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Background and Significance 
 
The human adult brain is highly metabolic, accounting for nearly a fourth of the 
body’s total oxygen and glucose consumption, despite only representing 2% of total body 
weight.  Additionally, the respiratory quotient (CO2 produced / O2 consumed) for the brain is 
nearly 1, indicating almost complete oxidation of glucose, and further suggesting that the 
brain is highly, if not exclusively, dependent on glucose as the sole energy producing fuel 
(Magistretti and Pellerin, 1996).  With these characteristics, it is easy to see how 
structural and functional abnormalities of the central nervous system (CNS) are common 
consequences of aberrant energy metabolism, especially when due to dysfunctional 
mitochondrial respiration.  The sensitivity of the CNS to energy deprivation is effectively 
demonstrated through examination of the various mitochondrial diseases (Brown and 
Squier, 1996).   
Mitochondrial diseases are a heterogeneous collection of metabolic disorders 
resulting from genetic abnormalities of mitochondrial and nuclear DNA responsible for 
encoding components of both the respiratory chain and pyruvate metabolism.  In general, 
the pathological responses of the brain to metabolic imbalance are relatively conserved 
with the most common outcomes being spongiform degeneration, neuronal loss, and 
extensive gliosis.  Though most MD’s present with one or more of these characteristics
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their regional distribution and degree of severity may differ widely.  These specific 
neuropathological changes are most commonly associated with Kearns-Sayre syndrome 
(KSS) and myoclonic epilepsy with ragged-red fibers (MERRF) in which defects in 
mitochondrial protein synthesis due to mutations of tRNA-encoding regions of mtDNA 
occur. (Lombes et al., 1989).     
Though there is considerable overlap in the pathology observed within the CNS 
for many of these metabolic disorders, some cases of MD’s present with sufficiently 
distinctive changes in the pattern of neuropathology that allows for specific diagnosis.  
For example, focal necrosis followed by calcification, predominantly in cerebral cortex, 
is a hallmark of mitochondrial encephalopathy, lactacidosis, and stroke like episode 
syndrome (MELAS).  Like KSS and MERRF, MELAS is due to a point mutation in a 
tRNA gene of mtDNA.  A second illustration of distinguishing neuropathology is Leigh’s 
necrotizing encephalopathy.  First described by Denis Leigh in 1951, Leigh’s syndrome 
encompasses a variety of molecular defects in components of mitochondrial 
bioenergetics, including complexes I, II, and IV of the respiratory chain as well as the 
pyruvate dehydrogenase complex and ATPase.  In Leigh’s syndrome, the most striking 
feature is bilaterally symmetrical spongiform degeneration with the relative sparing of 
neurons.  
The unique neuropathology encountered in Leigh’s disease results in its inclusion 
with acute energy deprivation syndromes (AEDS) due to the striking similarities in lesion 
presentation (Cavanagh, 1993).  Acute energy deprivation syndromes are a family of 
metabolic disorders with diverse etiologies, ranging from nutritional deficiencies, 
chemical intoxication to genetic abnormalities. Highly specific, regionally restricted 
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lesions within the neuraxis distinguish AEDS and like the analogous Leigh’s syndrome, 
AEDS present with bilaterally symmetrical focal lesions, predominantly affecting the 
brainstem.  The lesions are primarily gliovascular, with neuronal involvement being 
secondary to edema and loss of astrocytes.  Regional metabolic demand seems to play a 
large role in selective vulnerability but areas with similar or even greater energy demands 
are spared, suggesting other factors may determine lesion restriction. 
1,3-Dinitrobenzene (1,3-DNB) is one of several nitroaromatic compounds shown 
to produce the characteristic neuropathology of AEDS. Others include nitrobenzene, 
trinitrobenzene, and various nitroimidazoles such as metronidazole, and misonidazole.  
1,3-DNB is an important chemical intermediate used in the production of azo and aniline 
dyes as well as a byproduct in the production of the most widely used explosive, 
trinitrotoluene (TNT), (Cody et al., 1981).  Like other nitroaromatic compounds, 1,3-
DNB induces methemoglobinemia.  Chemical oxidation of the heme iron renders 
hemoglobin incapable of transporting oxygen to tissues.  Other clinical manifestations of 
1,3-DNB exposure include headache, nausea, tachycardia, numbness in the distal portions 
of the limbs and hearing loss (Cody et al., 1981; Philbert et al., 1987).  In addition to 
neurological defects incurred during exposure, animal studies have shown this compound 
to adversely affect male reproductive capacity.  The primary target in the testis being the 
supportive Sertoli cells, with subsequent loss of germ cells.   
Though the overall risk of exposure to the general population is relatively low, the 
ability of 1,3-DNB to mimic human metabolic diseases underscores its importance as a 
model to investigate fundamental mechanisms of acute energy deprivation syndromes.  
The molecular defects encountered in AEDS encompass multiple metabolic pathways, 
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including glycolysis, TCA cycle, mitochondrial respiration, and pentose phosphate 
pathway.  Specific metabolic targets have been identified for a majority of these 
metabolic disrupters responsible in acute energy deprivation syndromes.  6-
Aminonicotinamide, an anti-metabolite of nictotinamide, forms an inactive analogue of 
NADP, Which acts as a potent inhibitor of 6-phosphogluconate dehydrogenase, essential 
for the pentose phosphate pathway (Haghighat and McCandless, 1997).  α-Chlorohydrin, 
commonly used as a rodenticide, similarly to analogous 6-chlorosugars and 6-
deoxysugars, disrupts glycolysis through the inhibition of the glycolytic enzyme, 
glyceraldehyde-3-phosphate dehydrogenase (Brown-Woodman et al., 1978).  In Leigh’s 
Disease three specific gene products are affected due to mutations of both mitochondrial 
and nuclear DNA resulting in deficiencies in complex I, II and IV of the electron 
transport chain as well as the pyruvate dehydrogenase complex (PDHc) (Leigh, 1951; 
Rahman et al., 1996).  Acute thiamine deficiency greatly diminishes the activities of two 
key metabolic enzymes, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase 
complexes, both of which require thiamine as a cofactor.  At present, no direct targets of 
the nitroaromatic compound 1,3-dinitrobenzene have been determined.   
The cellular presentation and regional distribution of lesions in nitroaromatic 
compound toxicity most strikingly resembles that of thiamine deficiency, suggesting that 
both cases of AEDS and 1,3-DNB toxicity may have a similar defect in energy 
metabolism, specifically, thiamine dependent enzymes.  Thiamine, a precursor to the 
active coenzyme thiamine pyrophosphate, is a required cofactor for a family of 
mitochondrial metabolic complexes termed the α-keto acid dehydrogenase complexes, 
which includes PDHc, KGDHc and the branched chain α-ketoacid dehydrogenase 
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complex. These thiamine dependent enzyme complexes play crucial roles in oxidative 
energy metabolism and are essential to maintaining proper ATP production for cellular 
processes. 
Both, PDHc and KGDHc occupy key sites in aerobic energy metabolism.  
Pyruvate dehydrogenase complex is the entry point of carbohydrates into the 
tricarboxylic acid (TCA) cycle, regulating the rate of glucose oxidation through the 
production of acetyl-CoA.  α-Ketoglutarate dehydrogenase complex is an essential 
component of the TCA cycle and is also involved in glutamate metabolism.  Disturbances 
in either enzyme would greatly undermine cellular energy production and would 
ultimately result in cell demise.   
There is considerable evidence that points to these mitochondrial dehydrogenase 
complexes as potential targets for 1,3-dinitrobenzene.  As stated earlier, these complexes 
are affected during other instances of acute energy deprivation, including diet-induced 
thiamine deficiency and deficient enzyme activity due to genetic anomalies.  
Additionally, the nitroaromatic compound, metronidazole, has been shown to be 
converted to a thiamine analog capable of inhibiting thiamine pyrophosphokinase, the 
enzyme required for converting thiamine to the essential enzyme cofactor, thiamine 
pyrophosphate (Alston and Abeles, 1987).  Thiamine and thiamine pyrophosphate co-
administration with the nitroaromatic compound misonidazole affords some protection 
against the neurotoxic effects of this compound (Rose et al., 1983).   
The above evidence suggests that α-ketoacid dehydrogenase complexes are 
potentially relevant in 1,3-DNB neurotoxicity and molecular characteristics of the 
complexes further support this hypothesis.  The α-ketoacid complexes are extremely 
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large (10 Mda) enzyme systems made up of multiple copies of three main catalytic 
enzymes and two associated regulatory enzymes.  The complex geometry of these 
enzymes allow for sufficient substrate channeling of reaction intermediates from one 
active site to the next without release into the bulk media resulting in a “ping pong” 
mechanism of catalysis (Figure 1-1).  The catalytic core of these complexes consists of a 
thiamine dependent α-ketoacid dehydrogenase (E1), responsible for the rate limiting 
reaction of decarboxylation, which produces a 2-hydroxyethyl-TPP-carbanion 
intermediate.  This carbanion then undergoes nucleophilic attack of the bound lipoic acid 
moiety of dihydrolipoyltransacetylase, the (E2) component. The lipoic acid bound to each 
of the two lipoyl domains of E2, through a flexible lysine chain linkage, facilitates 
transfer of the bound acyl group to coenzyme A.  Lastly, dihydrolipoyl dehydrogenase, 
the (E3) component with a bound FAD+, re-oxidizes the reduced lipoic acid of E2 with 
concomitant production of NADH (Yeaman, 1989; Reed, 1998).  The first two 
components are substrate specific depending on the complex, with the third being 
universally expressed.  In addition to the catalytic components, PDHc contains a 
structural component, E3 binding protein (E3BP), which is responsible for binding the E3 
to the E2 core.  Like its E2 counterpart, this protein also contains a lipoyl domain with a 
bound lipoic acid though the function of this lipoic acid is not entirely understood since 
E3BP does not possess transacetylase activity.  The activity of α-keto acid 
dehydrogenase complexes is tightly controlled through a phosphorylation / 
dephosphorylation cycle that is mediated by a associated kinase and phosphatase bound 
to the lipoyl domains of the E2 component (Harris et al., 1997).  The structural 
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complexity of this enzyme complex matched with its strict cofactor requirements and 
tight metabolic regulation make it a prime target during many pathological conditions. 
The vicinal dithiol group of lipoic acid is extremely sensitive to oxidative 
modification.  As seen with arsenical compounds, protein adduction of this site is a 
common mechanism of inhibition.  Akin to the classic arsenite induced dysfunction, other 
compounds such as strong electrophiles have been shown to disrupt the activity of α-
ketoacid dehydrogenase complexes in a similar manner.  These inhibitors include the 
highly reactive α,β unsaturated aldehydes, 4-hydroxynonenal and acrolein, both 
produced during lipid peroxidation, and the ubiquinone analogue coenzyme Q0.  
Additionally, lipoic acid can be directly affected by both superoxide generation as well as 
hydroxly radicals (Tabatabaie et al., 1996).  Direct modification by reactive oxygen 
species is suggested to underlie the observed loss of PDHc during the reperfusion stage of 
ischemia/reperfusion injury (Zaidan and Sims, 1993).  The sensitivity of the essential 
cofactor, lipoic acid, to interference by either strong electrophiles or reactive oxygen 
species, further support the potential for PDHc and KGDHc activity to be disrupted by 
1,3-DNB exposure.   
During 1,3-DNB metabolism, both reactive oxygen species and strong 
electrophiles may be produced.  1,3-DNB undergoes a stepwise 6-electron reduction to 3-
nitroaniline (Figure 1-2).  Upon reduction, the highly reactive nitroxyl radical is formed 
and in the presence of molecular oxygen it is proposed that a futile redox cycle is 
established leading to the production of the reactive oxygen species, superoxide (Cossum 
and Rickert, 1985; Nystrom and Rickert, 1987; Jacobson and Miller, 1998).  Evidence for 
the induction of oxidative stress upon metabolism of 1,3-DNB is supported by the 
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increase in superoxide levels as well as rapid GSH depletion observed during exposure of 
astrocytes to 1,3-DNB (Ray et al., 1994; Tjalkens et al., 2003).  Following diminished 
cellular oxygen concentration, due to persistent redox cycling, the nitroxyl radical can be 
further reduced to the nitroso metabolite.  Subsequent 2-electron reduction results in the 
production of 3-nitrophenylhydroxyl amine.  Both nitrosoaromatics and hydroxylamines 
are strong electrophiles that have been shown to react with reduced sulfhydryls (Eyer, 
1979; Eyer and Schneller, 1983; Umemoto et al., 1988; Cribb et al., 1991).  It is plausible 
that either the induction of oxidative stress through the production of superoxide with 
subsequently formation of hydroxyl radicals or the presence of electophilic reductive 
metabolites of 1,3-DNB may result in the oxidative modification of protein bound lipoic 
acid.  Alternatively, lipid peroxidation may ensue post-oxidative stress induction 
resulting in the formation of reactive products that have already been shown to adversely 
effect α-ketoacid dehydrogenase complexes through adduction of lipoic acid moieties.    
The importance of metabolism in conferring neurotoxicity of 1,3-DNB is 
established through examination of the metabolic pathways for each of the three isomers.  
Only the 1,3 isomer is able to generate neurological dysfunction.  Differences in isomer 
specific metabolism are cited to be potentially responsible for the inability of the 1,2 and 
1,4 isomer to cause neurotoxicity.  The primary route of 1,2-DNB metabolism is 
conjugation to GSH with a high percentage of the initial dose being excreted as S-(2-
nitrophenyl)-N-acetylcysteine.  1,4-DNB appears to undergo both reduction as well as 
conjugation to GSH with the presence of both the reductive metabolites and the 
mercapturic acid conjugates being observed.  Conversely, 1,3-DNB selectively undergoes 
reduction (Nystrom and Rickert, 1987).  An interesting side note is that both the 1,3 and 
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1,4 isomers produce methemoglobinemia though only 1,3-DNB results in 
neuropathology, suggesting that diminished oxygen capacity is not the major mechanism 
of toxicity in 1,3-DNB induced encephalopathy.       
Additional support for the inhibitory action of 1,3-DNB or it metabolites on α-
ketoacid dehydrogenase complexes, comes from the finding that mono-nitroso-
nitrobenzene, a reductive metabolite of nitrobenzene, may undergo further metabolism by 
PDHc in the presence of 2-oxoacids including pyruvate.  This interaction of nitroso-
aromatic compounds with the enzyme prevents production of acetyl CoA due to transfer 
of the acetyl moiety to the highly reactive nitroso compound with subsequent formation 
of an N-hydroxy-N-arylacylamide (Yoshioka and Uematsu, 1993; Yoshioka et al., 1996). 
Investigations into the specific component responsible for the production of N-hydroxy-
N-arylacetamide by PDHc suggest that E1 catalyzed transacetylation is the step affected 
by nitosoaromatic compounds due to apparent proper execution of the first step being the 
decarboxylation of the α-ketoacid, pyruvate.  In normal catalytic cycles of PDHc the 
pyruvate derived acetyl group is transferred to the E2 bound lipoyl moiety with 
subsequent acetyl transfer to coenzyme A, forming acetyl CoA. It is proposed that, in 
substitution for the lipoic acid group of E2, nitrosobenzene occupies the transacetylation 
site of E1 producing N-hydroxy-N-phenylacetamide upon reductive acetylation.  PDHC 
catalyzed production of this highly reactive metabolite not only posses a threat due to its 
potential ability to form DNA adducts but it may also greatly compromise the enzymes 
capacity to perform its natural function (Yoshioka et. al, 1993).  Interference of acetyl-
CoA production by nitroso-aromatic compounds would greatly hinder cellular energy 
production.   
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Formation of 3-nitrosonitrobenzene (3-NNB), a proposed toxic species of 1,3-
DNB, as well as the possible inhibitor of PDHc, is an NADH / NAD(P)H dependent 
enzymatic process.  The enzyme(s) responsible for the 2-electron reduction of the nitro 
group have not been definitively identified.  Several enzyme systems have been reported 
to possess nitro reductase activity including xanthine oxidase, DT diaphorase and 
NADPH-cytochrome c reductase.  These enzyme systems reside predominantly in either 
the endoplasmic reticulum or cytosol.  Investigation into DNB metabolism by isolated 
seminiferous tubules, points to the mitochondria as the major site of reductive 
metabolism.  Whether or not this is the case for the brain has not been addressed. 
Examination of mitochondrial NADH-dependent nitro reductase activity, in rat brain, 
demonstrated significant activity toward 1,3-dinitrobenzene that was more then 50 times 
higher then the microsome and cytosol fractions (Kochli et al., 1980). 
Interestingly, one mitochondrial enzyme that has been shown to possess 
nitroreductase activity is lipoamide dehydrogenase, which is a component of the α-keto 
acid dehydrogenase enzyme complexes (Tsai, 1987).  The unique organization of an 
enzyme complex allows for tightly regulated shuttling of intermediates between 
component enzymes.  Lipoamide dehydrogenase, the E3 component of PDHC, may 
reduce 1,3-dinitrobenzene to the highly reactive nitroso intermediate allowing for this 
species to interact with the sulfhydryl groups of the lipoic acid moiety in the E2 
component.  The intrinsic flexibility of the lysine arm with bound lipoic acid, allows this 
element to swing back and forth between the E1 and E3 components of the complex.  
Upon interaction of the nitroso compound with the lipoic acid group it may be possible 
for the nitroso-nitrobenzene compound to bind the E2 complex allowing it to substitute 
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for lipoic acid at the transacetylation site.  This substitution would prevent production of 
acetyl-CoA, greatly affecting its ability to produce adequate ATP. 
The sensitivity of lipoic acid to oxidative modification, combined with the 
potential ability of lipoamide dehydrogenase to metabolize nitroaromatic compounds 
points to the α-ketoacid dehydrogenase complexes as likely targets for direct 
modification by 1,3-DNB or its reductive metabolites.  Alternatively, establishment of an 
oxidative environment through excess production of superoxide during 1,3-DNB 
metabolism may also result in dysfunctional enzyme activity either through direct 
interaction with reactive oxygen species or through induction of lipid peroxidation and 
production of reactive aldehydes capable of affecting the α-ketoacid dehydrogenase 
complexes.  The experiments described in this thesis aim to determine whether 1,3-DNB 
affect the α-ketoacid dehydrogenase complexes.              
In addition to investigating the potential biochemical targets of 1,3-DNB, this 
thesis also addresses the role of astrocyte / neuronal interactions in the initial sparring of 
neurons observed in the neuropathology of acute energy deprivation syndromes.  
Astrocytes perform numerous functions in the CNS including maintenance of the 
extracellular environment, formation and maintenance of the blood-brain barrier, as well 
as modulation of synaptic transmission.  The functions of astrocytes are due to the 
formation of intimate relationships with both neuronal and endothelial components in the 
CNS.  These relationships allow astrocytes to play an extremely important role in 
cerebral function, homeostasis, as well as in modulating toxicity. The ability of astrocytes 
to modulate physiological as well as pathological responses of neighbors cells in the CNS 
are accomplished through active signaling mediated by astrocyte-derived 
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neurotransmitters, termed gliotransmitters (Koizumi and Fujishita, 2007). One such 
gliotransmitter suggested to be involved in the intimate interaction between astrocyte and 
neurons as well as astrocytes and vascular endothelial cells is the purine, adenosine.    
Adenosine, a hydrolysis product of ATP, is a potent modulator of many 
physiological functions in various systems, particularly those of excitable tissues such as 
heart, and brain.  Under normal physiological conditions, adenosine concentrations in the 
extracellular space are in the nanomolar range but during times of energy deprivation, as 
seen in conditions of increased metabolic activity or in cases of hypoxia or ischemia, 
adenosine levels dramatically increase.  Peak levels on the order of 3 µM have been 
recorded in the striatum of rats following 24 hr of focal ischemia induced by occlusion of 
the middle cerebral artery (Melani et al., 1999).  Increased adenosine levels is followed 
by activation of suppressive signaling pathways resulting in compensatory actions such 
as vasodilation, cessation of neurotransmission, and diminution in cellular activity giving 
adenosine the distinction of a retaliatory signaling molecule (Yoon and Rothman, 1991).  
Interestingly, all these behaviors have been shown to occur in 1,3-DNB and other AEDS 
(Philbert et al., 1987; Cavanagh, 1988).  The induction of cellular signaling pathways by 
adenosine are mediated through activation of specific cell surface purinergic receptors 
aptly named the adenosine receptors (AR).  The AR family of G-protein coupled 
receptors is subdivided into 4 known isotypes (A1, A2a, A2b, and A3) based on their 
distinct pharmacological profiles, molecular structure and tissue distribution (Fredholm et 
al., 2000). There has been a recent expansion of interest in adenosine receptors due to the 
therapeutic prospects these receptors may hold in various pathological conditions 
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including diabetes, epilepsy, cancer, neurodegeneration, cardiovascular disease and 
stroke (Williams and Jarvis, 2000; Stone, 2005). 
Adenosine receptor activation results in the induction of numerous biochemical 
pathways.  Like other G-protein coupled receptors, AR’s modulate intracellular 
concentration of cAMP through their actions on adenyl cyclase.  In addition to cAMP 
dependent pathways other pathways are also activated including inositoltrisphosphate 
(IP3) and diacylglycerol (DAG) pathways.  Adenosine receptors have also been shown to 
influence the activity of the mitogen activated protein kinase (MAPK) including ERK 
(1/2). Activation of MAPK leads to phosphorylation of numerous proteins including 
transcriptional factors as well as proteins involved in regulating cell death (e.g.. Bcl-2; 
(Breitschopf et al., 2000).   
The Bcl-2 family proteins have been implicated in the control of cellular 
sensitivity to endogenous and exogenous stresses.  They are believed to regulate 
mitochondrial permeability transition, a term used to describe an abrupt increase in 
mitochondrial inner membrane permeability to solutes smaller then 1500 Da, through 
intimate interactions with a multi-protein pore (Lemasters et al., 1997). There are both 
pro (Bcl-2, Bcl-xl) and anti (Bax, Bid, Bad) members of the Bcl-2 family that interact 
with each other to regulate the fine line between life and death of a cell (Lindsten et al., 
2005). 
Control of apoptosis may be mediated through regulation of Bcl-2 family proteins 
via reversible phosphorylation.  Phosphorylation of Bcl-2 family proteins regulates many 
aspects of these proteins including translocation, degradation and interactions with other 
members of the family (Breitschopf et al., 2000).  Adenosine has been shown to activate 
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ERK 1/2 in perfused rat heart through activation of all 4 adenosine receptors (Germack 
and Dickenson, 2005).  Bcl-2 family proteins possess protein kinase consensus sites 
specific for ERK 1/2 suggesting that adenosine mediated regulation of apoptosis could be 
due to activation of ERK 1/2 and subsequent phosphorylation of Bcl-2 family proteins.   
The ability of 1,3-DNB to induce mitochondrial permeability transition in a 
regionally selective manner supports the potential role for Bcl-2 family proteins in 
facilitating regional and cell specific neurotoxicity seen in 1,3-DNB and other AEDS 
(Tjalkens et al., 2000; Tjalkens et al., 2003).  Consequently, regulation of Bcl-2 family 
proteins through induction of intracellular signaling pathways would also facilitate this 
selectivity.  It is conceivable that intercellular signaling between astrocytes and neurons, 
mediated through adenosine receptor activation, may result in the induction of pro-
survival mechanisms leading ultimately to cellular protection.       
In the preceding sections of this Introduction, substantial evidence was outlined 
supporting the potential for α-ketoacid dehydrogenase complexes as prime candidates 
responsible for the metabolic disruption induced by 1,3-DNB in the CNS.  The studies 
presented in the following chapters of this thesis were designed to test the hypothesis that 
1,3-DNB has the capability to elicit metabolic dysfunction through its actions on the α-
ketoacid dehydrogenase complexes and to examine the detailed mechanisms of this 
inhibition.  In the final data chapter, the role of astrocyte-neuronal interactions in 
mediating the effects of 1,3-DNB is presented.  Implications for the role of adenosine-
mediated signaling pathways are discussed with respect to neuroprotection.  Further 
investigations into the complex relationship between astrocytes and neurons during acute 
























Figure 1-1.  Catalytic cycle of the multi-component enzyme complex, pyruvate 
dehydrogenase complex as adapted from Horton’s “Principles of Biochemistry, 4 ed”.  
Pyruvate undergoes nucleophilic attack by the carbanion of E1-bound thiamine 
pyrophosphate with subsequent decarboxylation to form a hydroxyethyl-TPP 
intermediate. Next, the 2-carbon acetyl molecule is transferred to coenzyme A (CoA) by 
first bonding with the E2-bound lipoic acid, which then facilitates transacetylation of 
CoA, releasing acetyl-CoA.  The final step involves re-oxidation of the reduced lipoic 



































Figure 1-2.  Proposed mechanism for 1,3-dinitrobenzene metabolism (Jacobson et al., 
1998).  The first step in reductive metabolism of 1,3-dinitrobenzene is a single-electron 
reduction to the reactive nitroxyl anion radical.  In an oxygen rich environment, this 
radical species can redox cycle with molecular oxygen producing superoxide radical. 
Futile redox cycling results in reduced oxygen tension allowing for a second one electron 
reduction to 3-nitrosonitrobenzene. Further two electron reductions occur resulting in the 
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SELECTIVE INACTIVATION OF THE PYRUVATE DEHYDROGENASE 




Pyruvate dehydrogenase complex (PDHc), an essential multi-component enzyme system 
responsible for the production of acetyl-CoA from glycolytically derived pyruvate, links 
glycolysis to the TCA cycle.  The adult brain relies almost exclusively on the complete 
oxidation of glucose, making PDHc function critical in maintaining cerebral energy 
metabolism.  1,3-Dinitrobenzene (1,3-DNB) selectively affects glio-vascular components 
in distinct brainstem regions, resembling the early effects of acute energy deprivation 
syndromes (AEDS).  Both in vivo and in vitro studies point to metabolic disruption in 
1,3-DNB neurotoxicity, though the specific site of impairment is not known.  In the 
present study, the effects of 1,3-DNB and its reductive metabolite, 3-nitrosonitrobenzene 
(3-NNB) on PDHc and KGDHc activity were investigated using commercially available 
enzymes purified from porcine heart.  Both compounds rapidly and dose-dependently 
inhibited PDHc.  In contrast to PDHc, only 3-NNB showed significant inhibitory capacity 
toward KGDHc.  The isomer-specificity and substrate requirements suggest that the E1 
component enzyme is a primary target of 1,3-DNB.  This hypothesis was confirmed 
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through inhibition studies on the separated E1 component.  3-Nitrosonitrobenzene was 
also shown to affect PDHc mediated metabolism of 5,5’-dithiobis-(2-nitrobenzoic acid) 
(DTNB) suggesting that this compound interferes with E2 bound lipoic acid.  Though 
further investigation into the mechanism of inhibition is required, these data support the 
potential role of PDHc inhibition in the neurotoxic mechanism of 1,3-dinitrobezene 
exposure.   
 
Introduction 
 Nitroaromatic compounds are key intermediates used in the production of 
numerous industrial and commercial products including industrial solvents, dyes, plastics, 
and explosives (Harter, 1985).  Though important for the chemical industry, due to their 
abundant use, nitroaromatics also pose many environmental issues and potential health 
risks.  1,3-Dinitrobenzene (1,3-DNB), important in azo and aniline dye synthesis, as and 
a byproduct in the production of the most widely used explosive, trinitrotoluene (TNT), is 
a multi-target toxicant affecting both the reproductive and nervous systems (Cody et al., 
1981).  Accidental occupational exposure in humans produces methemoglobinemia, 
tachycardia, hearing loss, and various neurological deficits such as headaches, nausea, 
and vertigo.  In animal studies, 1,3-DNB exposure results in significant testicular 
dysfunction, with Sertoli cells being the primary target (Foster, 1989).  In addition to 
effects on male reproductive capacity, prolonged or repeated exposure to 1,3-DNB 
produces similar CNS lesions characteristic of acute energy deprivation syndromes 
(AEDS) (Philbert et al., 1987; Romero et al., 1991; Ray et al., 1992).  AEDS are a family 
of conditions, which include acute thiamine deficiency, the inherited neurometabolic 
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disorder Leigh’s necrotizing encephalomyelopathy, and chemical intoxication by various 
compounds such as chlorosugars, and 6-aminonicotinamide (Cavanagh, 1993).  All these 
conditions result in a distinctive bilaterally symmetrical lesion, with very similar regional 
distribution.  While lesion location may vary slightly depending on stimulus and species 
afflicted, the auditory and vestibular centers of the brainstem appear to be most 
commonly affected.  This is believed to be a result of high metabolic demand within 
these areas (Cavanagh, 1988).  Though regional metabolic activity appears to play a 
significant role in determining patterns of CNS damage in AEDS, other factors such as 
site of biochemical defect may be involved in the observed selective vulnerability.   
The commonality amongst all of these conditions is the disruption of key steps 
within the energy metabolism pathways.  In the case of nitroaromatic compounds, the 
specific site of metabolic impairment is not known.  Examination of the biochemical 
defects responsible for some AED syndromes including acute thiamine deficiency, 
metronidazole intoxication, and Leigh’s syndrome suggests that thiamine status or more 
importantly the activity of thiamine dependent enzymes is the key factor linking these 
particular cases of AEDS.  The compelling regional similarity in lesion presentation 
between these particular instances of AEDS and nitroaromatic compound exposure, and 
similar changes in biochemical parameters including increased glucose utilization and 
increased extracellular lactate, suggests that a possible target for nitroaromatic 
compounds may be thiamine dependent enzymes.           
 Thiamine, an essential precursor to thiamine pyrophosphate, is a required 
cofactor for α-ketoacid dehydrogenase complexes.  This family of multi-component 
complexes includes the branched chain α-ketoacid dehydrogenase (BCKDc), α-
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ketoglutarate dehydrogenase (KGDHc), and the pyruvate dehydrogenase (PDHc) 
complexes (Yeaman, 1989).  The α-ketoacid dehydrogenase complexes are extremely 
large (10 MDa), multi-component enzyme systems that are made up of 3 catalytic 
enzymes, two regulatory enzymes and require 5 cofactors. The three constituent enzymes 
that make up the catalytic core of these complexes are a substrate specific α-ketoacid 
decarboxylase (E1), a substrate specific acyltransacetylase (E2) and the shared 
dihydrolipoamide dehydrogenase (E3).  All three component enzymes act in concert to 
facilitate the following overall reaction (Tsai et al., 1973): 
                                                                             TPP, LA, FAD 
RCOCO2H + NAD+ + CoASH ========> RCO-S-CoA + CO2 + NADH + H+ 
 
The individual steps that make of the overall reaction are described below using pyruvate 
as the α-ketoacid: 
 
(1) CH3COCO2- + E1TPP + H+  <==> CO2 +E1CH3C(OH)=TPP 
(2) E1CH3C(OH)=TPP + E2-LipS2 <==> E1TPP + E2-Lip(SH)-S-COCH3 
(3) E2-Lip(SH)-S-COCH3 + CoASH <==> E2-Lip(SH2) + CH3COSCoA 
(4) E2-Lip(SH2) + E3FAD  < == > E2-LipS2 
 
The two complexes, PDHc and KGDHc, occupy critical sites in oxidative energy 
metabolism.  PDHc plays a unique role in energy metabolism by acting as a critical 
gateway linking glycolysis to the TCA cycle, through the production of acetyl-CoA.  This 
position assigns PDHc the important task of controlling the rate of complete oxidation of 
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carbohydrates (Wieland, 1983).  KGDHc, being equally as important, catalyzes a key 
step in the tricarboxylic acid cycle (TCA) and is also responsible for linking the TCA 
cycle to glutamate metabolism with the help of glutamate dehydrogenase.  Disturbances 
in the function of either of these two vital thiamine dependent enzyme systems frequently 
result in ensuing pathological states in those tissues that maintain a high aerobic rate, 
such as the brain.  Normally, the adult brain maintains a high demand for energy with low 
energy reserves and is highly, if not exclusively, dependent on the complete oxidation of 
glucose as the sole energy producing fuel (Ritter and Robertson, 1994).  These unique 
characteristics render the brain an extremely sensitive target to any disturbances in 
oxidative energy production and demonstrate the pivotal role both PDHc and KGDHc 
play in maintaining proper cerebral functioning.  Disturbances in the activity of these 
enzyme complexes have been implicated as potentially relevant in various neurological 
disorders including Wernicke’s encephalopathy (Butterworth et al., 1993), cerebral 
ischemia/reperfusion (Martin et al., 2005), and Alzheimer’s and Parkinson’s disease 
(Mizuno et al., 1994; Kish, 1997).  Similarly, these key metabolic enzymes may be 
relevant in the neurotoxicity observed during 1,3-DNB exposure. 
In the present study, the effects of 1,3-dinitrobenzene and its highly reactive 
intermediate, 3-nitrosonitrobenzene, on PDHc and KGDHc were determined using 
commercially available purified enzymes from porcine heart.          
. 
Materials 
Purified pyruvate dehydrogenase complex and α-ketoglutarate dehydrogenase 
complex from porcine heart were obtained from Sigma suspended in a 50% glycerol 
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solution containing 9 mg/ml bovine serum albumin, 30% sucrose, 1.5 mM EDTA, 1.5 
mM EGTA, 1.5 mM 2-mercaptoethanol, 0.3% TRITON X-100, 0.003% sodium azide, 
and 15 mM potassium phosphate, pH 6.8.  All other chemicals were obtained from Sigma 
unless otherwise stated.  
 
Methods 
Determination of PDHc and KGDHc activity  
Spectrophotometric assay 
A standard spectrophotometric assay was performed to determine the activities of 
PDHc and KGDHc as described previously (Hard et al., 2001) with minor alterations.  In 
brief, the formation of the reduced form of nicotinamide-adenine dinucleotide (NADH) 
was monitored at 340 nm at 30°C.  Commercially available porcine heart PDHc (15 
mg/ml) or KGDHc (10.2 mg/ml) were employed in this assay.  The reaction mixture 
contained 50 mM potassium phosphate buffer, pH 7.4, 2.5 mM NAD+, 0.2 mM thiamine 
pyrophosphate (TPP), 1 mM MgCl2, 1 mM pyruvate or α-ketoglutarate, PDHc (final 
concentration 75 µg/ml) or KGDH (final concentration 50 µg/ml).  Reaction buffer 
combined with the appropriate enzyme were incubated for 2 min at 30°C.  Varying 
concentrations of inhibitor were then added and incubated for an additional 3 min.  At 5 
min the reaction was started with addition of CoA (final concentration 0.2 mM).  The 
assay was performed on a Spectramax microplate spectrophotometer (Molecular Devices, 
Inc).  Absorbance data were fitted to equations that describe models of inhibition using 
Sigmaplot with the enzyme kinetics module (Systat).  Best-fit models were determined 
 27 
by comparing the sum of squares using non-linear regression and model selection was 
determined with the use of an F test.     
 To determine substrate requirements, as well as the potential for reversibility, 
PDHc was incubated with varying concentrations of 1,3-DNB in 50 mM potassium 
phosphate buffer, pH 7.4 containing various substrates as indicated in the figure legends.  
After exposure, samples of PDHc were taken and activity was determined as stated 
above.  Through this method 1,3-DNB concentrations were diluted 50 fold.  
Commercially available purified PDHc has been shown to be almost completely saturated 
with bound TPP (Strumilo et al., 2004).  In order to investigate thiamine’s role in 
inhibition by 1,3-DNB the removal of bound thiamine was necessary.   It was found that 
due to the size of PDHc, the complex can be pelleted, resulting in the removal of TPP 
(Sumegi and Alkonyi, 1983).  Briefly, PDHc diluted in 50 mM sodium phosphate buffer, 
pH 7.0 containing 5 mM EDTA was subjected to sedimentation by ultra-centrifugation at 
150,000 x g at 4°C for 2 hrs.  The pelleted complex was resuspended in reaction buffer 
minus substrates.   
 
HPLC method   
To determine PDHc activity, acetyl-CoA production was monitored using reverse 
phase high pressure liquid chromatography (HPLC) as described by Maehara et al., 1990.  
The reaction buffer used was the same as that employed in the spectrophotometric assay 
with one exception.  The concentration of pyruvate in the reaction buffer was increased to 
2 mM.  The reaction was initiated with the addition of CoA (final concentration 1 mM) 
and the reaction was allowed to proceed for 30 min, at which time, the reaction was 
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stopped by the addition of 70% perchloric acid (final concentration 6%).  Protein 
precipitate was removed by centrifugation at 8000 X g for 10 min.  Five µl of clear 
supernatant was injected into a Waters HPLC system equipped with a dual λ-absorbance 
UV detector and inline degasser.  Acetyl-CoA separation was performed by isocratic 
elution on a Symmetry 300™ C-18 column (4.6 x 1.5 mm, 5 µm) at a flow rate of 1 ml / 
min and peak absorbance was recorded at 254 nm.  The mobile phase consisted of 0.1 M 
sodium phosphate buffer, pH 4.0 containing 0.1 mM EDTA and 20% methanol.  The area 
under the curve was quantified and the concentration of acetyl-CoA was determined 
using a standard calibration graph.              
     
Separation of the E1 and E3 components of PDHc 
The individual components of the pyruvate dehydrogenase complex were 
separated by limited proteolysis and ammonium sulfate precipitations by a method 
described previously (Kresze et al., 1980).  Briefly, purified pyruvate dehydrogenase 
complex (5 mg/ml) was incubated with papain (35 µg/ml) in 0.1 M phosphate buffer, pH 
6.5, containing 2 mM cysteine, and 1 mM EDTA for 10 min at 25 °C with gentle stirring.  
The protein digestion was stopped with the addition of leupeptin (0.1 mg/ml) and the 
mixture was allowed to incubate for 15 min at 0°C. The solution was diluted in half with 
buffer A consisting of 20 mM potassium phosphate, pH 7.0, containing 1 mM MgCl2, 10 
µM thiamine pyrophosphate, 0.1 mM EDTA, 2 mM dithiothreitol, and 0.5 mM NAD.  
Proteolysis results in selective digestion of the E2 component, which causes dissociation 
of the two other components, the E1 and E3.  The nicked E2 was precipitated out using 
0.16 g of solid ammonium sulfate to produce a 28% saturated solution and incubated at 
 29 
0°C for 15 min.  To remove the precipitated nicked E2, the mixture was centrifuged at 
10000 x g for 20 min at 4 °C.  The clear supernatant was then made 59 % saturated by 
adding 0.19g of solid ammonium sulfate.  The precipitated E1 component was pelleted 
by centrifugation and redissolved in buffer A containing 0.1 mg/ml leupeptin. 
 
Determination of the activities of the separated E1 and E3 components 
E1 activity 
 
The pyruvate dehydrogenase (E1) activity was determined spectophotometrically 
by following the loss of absorbance of 2,6-dichlorophenolindophenol (DCPIP) (Alkonyi 
et al., 1976).  The reaction buffer consisted of 50 mM sodium phosphate buffer, pH 7.8, 
containing 2 mM MgCl2, 0.2 mM thiamine pyrophosphate and 0.2 mM DCPIP.  The 
reaction was initiated by addition of pyruvate, 0.2 mM final concentration.  The 
absorbance was monitored at 600 nm using a Spectramax microplate spectrophotometer 




The effects of 1,3-DNB on dihydrolipoamide dehydrogenase (E3) activity were 
determined using commercial preparations of purified E3 from porcine heart (13 mg/ml).  
The reaction buffer consisted of 50 mM sodium phosphate buffer, pH 7.4 containing 2.5 
mM NADH, and 1mM MgCl2.  The reaction was started with the addition of lipoamide, 3 
mM final concentration.  Loss of absorbance at 340 nm was recorded on a Spectramax 




Dithio-bis-nitrobenzoic acid (DTNB) assay  
To investigate the ability of 3-NNB to interfere with the lipoyl moieties of the E2 
component, the DTNB assay as described previously was employed (Humphries and 
Szweda, 1998).  It was necessary to remove β-mercaptoethanol present in the packaging 
solution of commercial PDHc, due to nonenzymatic reduction of DTNB.  The complex 
was pelleted as described above and was resuspended in 50 mM sodium phosphate 
buffer, pH 7.4.  The sulfhydryls of lipoic acid were reduced by the addition of 100 µM 
NADH for 10 min.  The reduced complex was then incubated with varying 
concentrations of 3-NNB for 10 min.  The reaction was started with the addition of 0.5 
mM DTNB and 100 µM NADH and the rate of DTNB reduction was followed at 412 nm 
at 30 °C on a Spectramax microplate spectrophotometer.  
     
Results 
 
1,3-DNB and 3-NNB impairment of PDHc and KGDHc 
 
Incubation of purified porcine heart PDHc with 1,3-DNB resulted in rapid 
inhibition as determined by a standard spectrophotometric assay (Figure 2-1).  The 
degree of impairment responded in a dose-dependent manner, with approximately 12% at 
the lowest dose of 5 µM and greater than 90% inhibition at 1 mM 1,3-DNB.  The IC50 for 
1,3-DNB impairment of PDHc was approximately 62 µM.  In contrast to PDHc, KGDHc 
showed dramatically less inhibition when incubated with 1,3-DNB with significant 
inhibition being observed only at 1,3-DNB concentrations above 500 µM.  IC50 for 1,3-
DNB-mediated inhibition of KGDHc could not be accurately determined.  Loss of total 
PDHc activity was confirmed using HPLC quantification of acetyl-CoA production 
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(Figure 2-2).  1,3-DNB impaired PDHc-mediated production of acetyl-CoA in a dose-
dependent manner.  Significant loss of acetyl-CoA production was observed at 50 µM 
and greater than 70% at 1 mM 1,3-DNB.  To further investigate the mode of inhibition, 
kinetic data were fitted to equations describing the different models of inhibition (figure 
2-3).  The best-fit model was determined through comparing the sum of squares obtained 
for each model and performing an F-test.  The model describing mixed inhibition had the 
lowest sum of squares supporting the conclusion that inhibition of PDHc occurs through 
a mixed type mechanism.     
 Exposure to 3-NNB, a highly reactive reductive metabolite of 1,3-DNB, resulted 
in significant inhibition of both the PDHc and KGDHc complexes.  Similar to the results 
obtained with 1,3-DNB, KGDHc appeared to be less sensitive to inhibition by 3-NNB 
(IC50 42.7 µM for KGDHc versus 7.82 µM for PDHc) though in contrast to 1,3-DNB, 3-
NNB was able to elicit almost complete inhibition by the highest dose of 1 mM (figure 2-
4).      
Isomer specificity 
Incubation of PDHc with each of the three isomer forms of dinitrobenzene 
revealed isomer specific inhibition (figure 2-5).  Both, the meta- and ortho- isomers 
showed comparable inhibition with approximate IC50’s of 46 µM.  In contrast, the para- 
substituted dinitrobenzene showed a significant reduction in inhibitory potential with an 
approximate IC50 of 325 µM.  The final nitroreduction product, 3-nitroaniline, showed 





To determine the ability of 1,3-DNB to elicit inhibition through irreversible 
binding of PDHc, 1,3-DNB at 500µM was incubated with PDHc in buffer for 5 or 90 min 
(Figure 2-6).  Enzyme with the inhibitor i.e. 1,3-DNB was diluted with an excess of 
reaction buffer (1:50 v/v) resulting in a final concentration of 10 µM.  Pre-incubation for 
both 5 and 90 min resulted in less than 20% inhibition.  This corresponds to the amount 
of inhibition obtained with co-incubation of PDHc with 10 µM 1,3-DNB.  Whereas, co-
incubation of PDHc with 500 µM 1,3-DNB results in greater then 85% inhibition.  
Activation of the complex with the addition of thiamine pyrophosphate (TPP) prior to the 
addition of 1,3-DNB resulted in 17% loss of PDHc activity, which is slightly higher than 
that observed with 10 µM co-incubation (figure 2-6b).  Addition of the substrate pyruvate 
to the complex prior to incubation with 500 µM 1,3-DNB resulted in slightly greater 
inhibition than that observed with TPP alone.  In contrast, incubation with both TPP and 
pyruvate followed by 1,3-DNB resulted in approximately 80% inhibition which 
corresponded to the amount of inhibition that was obtained with co-incubation of 500 µM 
1,3-DNB.  
DTNB reduction assay 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) has previously been shown to bind 
reduced E2-bound lipoic acid with subsequent catalytic cleavage by lipoamide 
dehydrogenase, the E3 component of the complex ((Brown and Perham, 1976; 
Humphries and Szweda, 1998).  Exploiting this reaction of DTNB with PDHc, it was 
possible to investigate the potential for 3-NNB to bind the E2 LA.  As shown in figure 2-
7, the ability of PDHc to metabolize DTNB was diminished by incubation of reduced 
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complex with increasing concentrations of 3-NNB suggesting that this strong electrophile 
is able to bind to reduced lipoic acid and may underlie the loss of activity of the complex.           
Component enzyme activities 
To further determine which component is affected by 1,3-DNB and its metabolite 
3-NNB, PDHc was separated into it component enzymes through limited proteolysis by 
incubation with papain.  This process affectively cleaves the E2 binding domains, 
releasing the bound E1 and E3 components without loss of component enzyme activity.  
No significant effects were observed with either 1,3-DNB or 3-NNB on the activity of E3 
component (Figure 2-8a).  Incubation of the E1 component with 1,3-DNB or 3-NNB 
resulted in significant inhibition.  3-NNB is a more potent inhibitor than its parent 
compound 1,3-DNB, with a calculated IC50 of 21 µM versus 762 µM for 1,3-DNB 
(Figure 2-8b).           
 
Discussion 
Disturbance in the metabolic function of astrocytes is a key component in the 
pathological mechanism of 1,3-dinitrobenzene-mediated encephalopathy, though the 
specific metabolic target of this compound is still unknown.  Astrocytes actively play an 
important role in neurological function requiring high amounts of available energy.  
These functions include maintenance of the brain microenvironment, such as regulation 
of excitatory neurotransmitters and ion homeostasis, as well as blood brain barrier 
facilitation and regulation of synaptic transmission (Rubin et al., 1991; Shao and 
McCarthy, 1994; Chen and Swanson, 2003).  Loss of available ATP pools through 
inhibition of essential metabolic enzymes would greatly compromise the ability of 
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astrocytes to maintain proper function and would result in neuropathology.  The present 
study was undertaken to investigate the potential for 1,3-dinitrobenzene or its reductive 
metabolite 3-NNB to interfere with the activity of the key metabolic super complexes, 
PDHc or KGDHc.   
1,3-DNB and the reductive metabolite, 3-NNB, both showed dose-dependent 
inhibition of PDHc activity with 3-NNB being greater than 5-fold more potent (Figure 2-
4a).  This disparity in effectiveness between 3-NNB and 1,3-DNB has also been observed 
in the ability of these compounds to elicit toxic outcomes in Sertoli cells, the primary 
target in 1,3-DNB-induced testicular toxicity (Cave and Foster, 1990).  These studies 
suggest 1,3-DNB can be bio-activated through nitroreduction to 3-NNB and become a 
more cytotoxic species.  Various nitroso-aromatic compounds can act as substrates for 
PDHc, as well as other α-ketoacid dehydrogenase complexes, resulting in the production 
of the proximate carcinogens, N-hydroxy-N-arylacetamides (Yoshioka and Uematsu, 
1993). The first step in normal catalytic function of PDHc is the E1-catalyzed 
decarboxylation of pyruvate with the formation of 2-(1-hydroxyethylidene)-TPP.  This is 
followed by reductive acetylation of E2 bound lipoyl moieties (Jordan, 2003).  It is 
thought that nitroso aromatic compounds replace the endogenous transacetylation site and 
are reductively acetylated in its place to form the corresponding N-arylhydroxamic acids.  
Due to this interaction with nitroso-aromatic compounds, pyruvate-derived acetyl-groups 
are diverted from their intended recipient, CoA, resulting in depletion of acetyl-CoA.  
This loss of the endogenous product of PDHc would cripple the cell’s ability to produce 
ATP and would result in cellular demise.  Metabolism of nitrosoaromatics to there 
respective N-hydroxy-N-arylacetamides has been shown to occur in numerous isolated 
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cells and perfused organs and is believed to occur in virtually all mammalian tissues 
(Yoshioka et al., 1996).  During this metabolism of nitrosoaromatics by PDHc, it was 
observed that bulky para-substituents on the aromatic ring reduced the enzymatic 
efficiency of the reaction.  This reduction in efficiency was attributed to steric limitation 
of the E1 component active site (Yoshioka and Uematsu, 1993).  Interestingly, 
examination of the three isomers of dinitrobenzene shows similar effects with respect to 
DNB inhibition of PDHc.  The para-substituted DNB showed significantly lower ability 
to inhibit the complex, while both the ortho- and meta- isomers show comparable 
inhibition.  The parallels between loss of catalytic efficiency and loss of inhibitory 
potency with para-substituted compounds support a common site of action.  This is 
further reinforced by substrate activation requirements.  Pre-activation of the complex by 
both, TPP and pyruvate, is required for substantial inactivation of PDHc by 1,3-DNB.  
This substrate requirement points to the involvement of the hydroxyethyl-TPP 
intermediate as key to the inhibition by 1,3-DNB.  This intermediate is in equilibrium 
with the enamine or 2nd carbanion, which normally undergoes nucleophilic attack of the 
disulfide bond of E2 bound lipoic acid.  In the production of N-hydroxy-N-
arylacetamides the nitrosoaromatic, a strong electrophile, takes the place of LA.  The 
ability of 3-NNB to inhibit the E1 component activity of PDHc supports the potential for 
direct nucleophilic attack by the carbanion.  Conversely, the lowered capacity of 1,3-
DNB to affect E1 activity again supports the need for bio-activation in order to disrupt 
PDHc activity.   
In contrast to PDHc, 1,3-DNB does not significantly affect KGDHc activity, 
though 3-NNB demonstrated comparable inhibitory potency towards both complexes.  
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This suggests that there is potentially a bio-activation of 1,3-DNB with respect to PDHc, 
which is not present in KGDHc.  The two enzyme complexes are very similar and 
accordingly would be expected to respond equally to the compounds.  Examining the two 
complexes lends some insight into a potential explanation for this unexpected 
discrepancy.  Both KGDHc and PDHc are made up of 3 catalytic components and 2 
regulatory ones.  In addition to these, PDHc also has an additional structural component, 
designated as the E3 binding protein (E3BP).  E3BP is responsible for binding the E3 
component to the E2 structural core and is essential for the catalytic activity of the overall 
complex.  Its value is demonstrated by an 80 to 90 percent reduction in PDHc activity in 
those individuals who genetically lack E3BP (Aral et al., 1997).  The E3BP, like its E2 
counterpart, possesses a subunit binding domain, a C-terminal domain and an N-terminal 
lipoyl domain with a covalently bound lipoic acid.  In contrast, the C-terminal domain of 
E3BP lacks the conserved active site histidine essential for acetyltransferase activity 
(Harris et al., 1997).  Recent architectural studies on PDHc proposed that the E3BP and 
the E3 component form sub-complexes at a ratio of 2:1, respectively (Smolle et al., 
2006).  This formation allows for cross bridging and also imparts a certain degree of 
restriction in the movement of the E2 and E3BP lipoyl-lysine flexible arms.  Originally it 
was thought that the flexible lipoyl lysine arms of E2 and E3BP were able to visit all 
three active sites of the individual catalytic components.  The new ultra-structural model 
suggests that the E2-lipoyl domains interact exclusively, or at least preferentially, with 
the E1 component while the E3BP-lipoyl domain interacts with the E3 component.  If 
this model were correct, the electron flow from reduced lipoamide on the E2 to NAD+ 
would have to go through the E3BP-lipoamide, supporting more than just a structural role 
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for this component.  Lipoamide dehydrogenase, the E3 component of the complex, has 
been shown to reductively metabolize nitro-aromatic compounds to their corresponding 
reductive metabolites including the reactive nitroso intermediate (Tsai, 1987).  The 
highly ordered arrangement of the catalytic components in the complex allows for 
efficient substrate channeling of reaction intermediates between the three active sites 
without release into the bulk media (Reed, 1974).  It is conceivable that E3-mediated 
reductive metabolism, of the parent nitro-aromatic compound, would produce highly 
reactive intermediates including 3-NNB with direct access to the E3BP lipoic acid moiety 
and subsequently E2 and E1 active sites.  
Lipoic acid, an essential coenzyme of the E2 component of PDC, consists of two 
vicinal sulfhydryl groups that are highly susceptible to oxidative modification.  3-NNB is 
extremely reactive towards sulfhydryls and interaction with the E2 bound lipoamide 
would directly position it at the transacetylation site, where by, it could accept the acetyl 
group from the 2-(1-hydroxyethylidene)-TPP with subsequent formation of the N-
arylhydroxamic acid.  Inhibition of PDHc-mediated DTNB reduction by 3-NNB further 
supports the interaction of this reactive intermediate with the sulfhydryls of LA.  DTNB 
was shown to bind reduced sulfhydryls of lipoic acid within the E2 component of PDHc 
and is subsequently cleaved by lipoamide dehydrogenase (E3) (Erfle and Sauer, 1968).  
This reaction was blocked by addition of N-ethylmaleimide, known to bind sulfhydryls 
(Brown and Perham, 1976).  Incubation of 3-NNB with PDHc in the presence of NADH 
resulted in loss of DTNB reduction suggesting that 3-NNB interferes with binding of 
DTNB potentially by adducting lipoic acid sites.  Further investigation into the ability of 
3-NNB to bind to the sulfhydryl groups on the E2-bound lipoyl moieties are required.   
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If E3 in fact does metabolize DNB to the nitroso- with subsequent adduction to 
lipoamide on the E3BP, the E3BP protein could potentially facilitate transfer of the 
nitroso-compound to the E2 lipoamide and consequently result is disruption of 
transacetylation.  The absence of E3BP in KGDHc may explain the greatly diminished 
impairment of this specific complex by 1,3-DNB.  Additionally, modification of E3BP-
lipoamide alone could disrupt transacetylation through interruption of lipoamide re-
oxidation, which is required for the acceptance of subsequent acetyl groups.  The 
involvement of E3BP in the mechanism of DNB-mediated inhibition of PDC is currently 
under investigation and potentially may shed some light on E3BP’s role in overall 
complex activity.           
In conclusion, the present study establishes PDHc as a potential target of direct 
inhibition by 1,3-DNB and its highly reactive reductive intermediate, 3-NNB.  The 
inhibition occurs through a mixed type mechanism and appears to require substrate 
activation prior to inhibition.  The ability of 3-NNB to potently inhibit E1 component 
activity suggests that direct attack of the strongly electophilic nitroso- group by the 
nucleophilic carbanion of 2-(1-hydroxyethylidene)-TPP may underlie its potent inhibition 
of the complex but does not rule out the potential of this thiol reactive compound from 
adducting the reduced sulfhydryls of E2 bound lipoic acid.  The relatively lower capacity 
of 1,3-DNB to inhibit the E1 component suggests an alternative mechanism of inhibition 
and points to the potential need for bio-activation for inhibition.  The differential effects 
observed between PDHc and KGDHc with respect to inhibition by 1,3-DNB further 
supports the need for bio-activation.  Though, further studies into the direct mechanism 
of inhibition are required, it is apparent that these compounds have the potential to affect 
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the activity of these essential metabolic enzyme complexes and would ultimately result in 















































Figure 2-1.  Differential effects of 1,3-DNB on the enzymatic activities of purified 
porcine heart 2-oxoacid dehydrogenases. Data expressed as percent inhibition (initial 





















































Figure 2-2. Effects of 1,3-DNB of the production of Acetyl-CoA by porcine heart 
pyruvate dehydrogenase complex.  A) Representative chromatograms of reaction 
supernatant after 60 min.  B) Graphical representation of acetyl-CoA concentrations 
determined by reverse phase HPLC and expressed as µg/ml (n=6).  * denotes significant 
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Figure 2-3. Double reciprocal plots of pyruvate dehydrogenase complex incubated with 
1,3-DNB while varying substrate concentrations A) Pyruvate B) CoA. Employing 
Sigmaplot® with the enzyme kinetics module (Systat Inc.) the data was analyzed with 
non-linear regression and the results were fit to equations which describe the four types 
of inhibition. The predicted velocity values in the presence of inhibitor were fit to the 
different models of inhibition and goodness of fit was determined by the calculated sum 

















































Figure 2-4. Comparison between the inhibitory effects of 1,3-dinitrobenzene and 3-
nitrosonitrobenzene on the enzymatic activities of purified porcine heart 2-oxoacid 
dehydrogenases. Data expressed as percent inhibition (initial velocities) relative to 















































































































Figure 2-5. Comparison of the three isomers (meta, para, ortho) of DNB and the final 
reductive metabolite (3-NA) on the activity of porcine heart pyruvate dehydrogenase 
complex. Data expressed as percent inhibition (initial velocities) relative to vehicle 



















































Figure 2-6. (a) Pre-incubation versus co-incubation of varying concentrations of 1,3-
DNB.  Data expressed as % inhibition +/- SE, relative to vehicle control (n=4).  (b) 
Substrate pre-activation requirements for inactivation by 1,3-DNB.  Data expressed as % 
PDHC activity (initial velocity) relative to vehicle control +/- SE (n=4). * denotes 
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Figure 2-7. Effects of 3-NNB on porcine heart pyruvate dehydrogenase complex 
mediated reduction of dithio-bis-nitrobenzoic acid.  Data expressed as percent inhibition 
+/- SE relative to vehicle control (n=4). (*) denotes significant difference from DMSO 














































































Figure 2-8.  Effects of 1,3-DNB and 3-NNB on the E1 and E3 component enzymes of 
PDHc. (A) Both 1,3-DNB and 3-NNB show no significant effects on E3 activity.  Data 
expressed as mean percent control +/- SE (n=6).  (B) 3-NNB and 1,3-DNB show 
significant inhibition of the E1 component with 3-NNB being more potent. IC50 for 3-
NNB and 1,3-DNB are approximately 21 µM and 762 µM, respectively. Data expressed 
as mean percent inhibition relative to DMSO control.  (*) denotes significant difference 
from DMSO control (P<0.01) (n=6).  (a) denotes significant difference between 1,3-DNB 
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1,3-DINITROBENZENE INDUCES METABOLIC IMPAIRMENT IN C6 




Prolonged exposure to the chemical intermediate, 1,3-dinitrobenzene (1,3-DNB), 
produces neuropathology in the CNS of rodents analogous to those observed in various 
conditions of acute energy deprivation.  Though the specific site of impairment is 
unknown, the metabolic status of astroglia, in susceptible regions, is compromised.  The 
effects of 1,3-DNB on metabolic status and inhibition of pyruvate dehydrogenase 
complex were evaluated using rat C6 glioma cells in culture.  Exposure of C6 gliomas to 
1,3-DNB resulted in altered morphology and biochemical dysfunction consistent with 
disruption of oxidative energy metabolism.  Both PDHc and KGDHc were affected by 
1,3-DNB in a concentration-dependent manner, with PDHc being more sensitive to 
inhibition.  Loss of lipoic acid (LA) immunoreactivity associated with protein carbonyl 
formation was a hallmark feature of in vitro exposure to 1,3-DNB.  Addition of 
antioxidants and thiol containing compounds failed to attenuate the loss of LA 
immunoreactivity.  These data support the hypothesis that 1,3-DNB impaired oxidative 
metabolism by the specific inhibition of the pyruvate dehydrogenase complex and that 
this impairment is due to perturbations in the function of protein-bound lipoic acid.  The 
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inability of antioxidants to affect the loss of LA by 1,3-DNB points to the direct oxidative 
modification of PDHc by 1,3-DNB or one of its reactive intermediates, and presumably 
not to increased production of reactive oxygen species and subsequent protein oxidation. 
 
Introduction 
Acute energy deprivation syndromes (AEDS; Cavanagh, 1988) are typified by 
gliovascular lesions in the auditory and vestibular regions of the brainstem.  The regional 
distribution of lesions are similar to that produced by a broad spectrum of mutations, 
deletions and mis-arrangements of both mitochondrial and nuclear DNA encoding 
components of the mitochondrial respiratory chain and pyruvate metabolism (Brown and 
Squier, 1996).  Consequently, perturbations in energy metabolism produce early CNS 
damage in conserved regions of the brainstem and result in human diseases such as 
Leigh’s necrotizing encephalopathy.  Rodent models of this mitochondrial disease are 
produced by a wide variety of metabolic disruptors including dietary induced vitamin B1 
deficiency, anti-metabolites such as pyrithiamine and 6-aminonicotinamide, and chemical 
intoxication by nitrobenzenes, nitrotoluenes, nitroimidazoles and deoxy-chlorosugars 
(Cavanagh, 1993). Though topographic distribution of the lesion varies depending on the 
chemical and the animal species afflicted, auditory and vestibular centers in the brainstem 
and deep cerebellum are frequent targets, which is consistent with their high metabolic 
demand.   
Acute energy deprivation syndromes are characterized by bilaterally symmetrical 
spongiform lesions, that involve swelling of astrocytes, followed by retraction of 
perivascular foot processes, and extensive cytoplasmic vacuolation (Philbert et al., 1987).  
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The underlying cellular mechanisms responsible for the regional and cell-specific 
sensitivity in these conditions are not well understood, however, molecular targets have 
been identified.  For example, 6-aminonicotinamide is a potent inhibitor of 6-
phosphogluconate dehydrogenase, essential for the pentose phosphate pathway 
(Haghighat and McCandless, 1997).  Similarly, α-chlorohydrin disrupts the metabolism 
of sugars through the inhibition of the glycolytic enzyme, glyceraldehyde-3-phosphate 
dehydrogenase (Brown-Woodman et al., 1978).  In Leigh’s disease, three specific gene 
products are affected due to mutation of both mitochondrial and nuclear DNA resulting in 
deficiencies in complex I, II and IV of the electron transport chain as well as the pyruvate 
dehydrogenase complex (PDHc) (Leigh, 1951; Rahman et al., 1996).  Acute thiamine 
deficiency greatly diminishes the activities of two key metabolic enzymes, PDHc and the 
α-ketoglutarate dehydrogenase complex (KGDHc) both of which require thiamine as a 
cofactor.  In the case of the nitroaromatics, mono- and di-nitrobenzene, the specific 
biochemical pathway that is affected is not completely known.  Nevertheless, the regional 
distribution and severity of the lesions produced by nitroaromatic chemicals most closely 
resemble that of thiamine deficiency, suggesting that these AEDS may have similar 
defects in energy metabolism mediated by thiamine dependent enzymes.   
Thiamine, a precursor to the active coenzyme thiamine pyrophosphate, is a 
required cofactor for a family of multi-component complexes termed the α-keto acid 
dehydrogenase complexes, which includes PDHc, KGDHc and the branched chain α-
ketoacid dehydrogenase complex.  PDHc and KGDHc occupy critical sites in energy 
metabolism.  PDHc is responsible for linking glycolysis to the TCA cycle through 
irreversible oxidative decarboxylation of pyruvate and subsequent formation of acetyl 
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coenzyme A (Patel and Roche, 1990).  KGDHc, being equally important, catalyzes a key 
step in the TCA cycle and is also responsible for linking the TCA cycle to glutamate 
metabolism with the help of glutamate dehydrogenase.  The complexes are made up of 
multiple copies of three main catalytic enzymes and also contain two regulatory enzymes.  
The catalytic core of PDHc consists of the pyruvate dehydrogenase (E1) component, 
which is responsible for the rate limiting reaction of decarboxylation with the use of 
thiamine pyrophosphate.  The second catalytic component, dihydrolipoyltransacetylase 
(E2) catalyzes the transfer of pyruvate derived acetyl groups to coenzyme A.  A lipoic 
acid bound to each of the two lipoyl domains of E2, through a flexible lysine chain 
linkage, facilitates this transfer.  Lastly, dihydrolipoyl dehydrogenase (E3) is charged 
with the re-oxidation of reduced lipoic acid of E2 with concomitant production of NADH 
(Yeaman, 1989; Reed, 1998).  In addition to the catalytic components, PDHc contains a 
structural component designated as the E3 binding protein (E3BP), which is responsible 
for binding the E3 to the E2 core.  This protein also contains a lipoyl domain with a 
bound lipoic acid though the function of this lipoic acid is not entirely understood since 
E3BP does not possess transacetylase activity (Harris et al., 1997).  PDHc activity is 
tightly controlled through a phosphorylation / dephosphorylation cycle that is mediated 
by pyruvate dehydrogenase kinase (PDHK) and pyruvate dehydrogenase phosphatase 
(PDHP) bound to the lipoyl domains of the E2 component (Harris et al., 1997).  The 
structural complexity of this enzyme complex matched with its strict cofactor 
requirements and tight metabolic regulation make it an attractive target during many 
pathological conditions.  
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Chemical modification of protein bound lipoic acid is considered a primary 
mechanism for inhibition of PDHc.  Classically, this is demonstrated by arsenical 
compounds, which have a high affinity for vicinal dithiols resulting in the formation of 
stable dithioarsinites (Samikkannu et al., 2003).  Additionally, various strong 
electrophiles such as the ubiquinone analog, coenzyme Q0, and the reactive lipid 
peroxidation products, 4-hydroxynonenal and acrolein, have shown a similar mechanism 
of action of forming stable adducts on lipoic acid (Humphries and Szweda, 1998; 
Pocernich and Butterfield, 2003; MacDonald et al., 2004).  Direct inactivation of PDHc 
by reactive oxygen species has also been reported (Tabatabaie et al., 1996).       
1,3-DNB undergoes nitroreduction to the final product 3-nitroaniline (Cossum 
and Rickert, 1985; Nystrom and Rickert, 1987).  In the proposed mechanism, the reactive 
intermediate nitroxyl anion radical is formed, which can potentially react with molecular 
oxygen to produce the reactive oxygen species superoxide with regeneration of the parent 
compound (Mason and Josephy, 1985).  The potential of nitroaromatic compounds to 
undergo futile redox cycling resulting in the increased production of superoxide suggests 
that like other neurological disorders, ROS production and subsequent oxidative damage 
of proteins may underlie the metabolic disruption induced by these compounds.  
Furthermore, during nitroreduction of 1,3-DNB, highly reactive electrophilic 
intermediates can also be produced offering an additional route to protein modification 
and subsequent functional disruption.   
The present study was undertaken to determine if 1,3-dinitrobenzene mediated 
metabolic impairment is associated with loss of PDHc activity and if so, what 
mechanisms underlie the disruption of this key metabolic enzyme. 
 56 
Materials 
Cell culture media and supplements were obtained from Invitrogen.  BCA protein 
quantification reagents and bovine serum albumin (BSA) standards were obtained from 
Pierce.  Precision plus molecular weight standards were purchased from Bio-Rad.  PVDF 
membrane was purchased from Milli-Pore.  Rabbit anti-lipoic acid antibody was obtained 
from Calbiochem.  Chicken anti-E2 subunit of PDHc and goat anti-chicken-alkaline 
phosphatase antibodies were obtained from Abcam.  All other reagents were purchased 




Rat C6 glioma cells, obtained from the American Type Culture Collection, were 
maintained at 37°C under an atmosphere of 5% CO2 / 95% air (v/v) in Dulbecco’s 
modified eagles medium (DMEM) supplemented with 10% fetal bovine serum and 1x 
antibiotics (Penicillin, Streptomyosin, and Neomycin).  Cells were subcultured using 
0.25% trypsin and used 48hrs after plating.  Prior to treatment, cells were rinsed with 




C6 glioma cells plated in 6 well plates were dosed with 1,3-DNB (250 µM, 500 µM and 
1 mM) for 36 hr.  Plates were then washed twice with D-PBS and phase-contrast light 
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microscopy was performed using an Olympus CKX41 inverted microscope equipped 
with a Spot Insight QE digital CCD camera.  
 
Cytotoxicity 
Mitochondrial reducing potential  
Cytotoxic effects of 1,3-DNB on C6 glioma cells were determined by monitoring the 
reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) as 
described (Mosmann, 1983).  The yellow, soluble tetrazolium dye is metabolically 
reduced to a purple, water-insoluble formazan, which is detected by a spectrophotometer.  
Cells plated in a 96 well microtiter plate were dosed with increasing concentrations of 
1,3-DNB.  After exposure, wells were rinsed with D-PBS and MTT assay solution (1 
mg/ml in DMEM) was added to each well and allowed to incubate for 2 h at 37°C.  MTT 
solution was then aspirated and 100 µl of DMSO was added to dissolve the formazan 
precipitant.  After 30 min incubation with vigorous mixing, the absorbance was 
determined at 550 nm.  Mean absorbance values were compared to vehicle control and 
IC50 values were determined by fitting data to a sigmoidal dose-response equation using 
Prism software (Graph Pad Software, Inc., San Diego, Ca). 
LDH release 
Cell death was measured by monitoring the release of lactate dehydrogenase into the 
culture medium.  Prior to exposure, cells in 24 well plates were rinsed with D-PBS and 
glucose free or glucose containing media was added to the cells for 1 hr.  The cells were 
then incubated with varying concentrations of 1,3-DNB.  After 24 hr exposure to 1,3-
DNB in the presence or absence of glucose (4500 mg/l), culture medium was removed 
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and placed in microcentrifuge tubes.  Samples were clarified by centrifugation (2000 x g, 
for 5 min at 4°C).  Lactate dehydrogenase concentrations were determined using a 
COBAS FARA II centrifugal analyzer (Roche diagnostics, Indianapolis, IN) employing a 
commercial reagent (LD-L) from Sigma Diagnostics as described in provided manual.    
 
Determination of Cellular ATP Content 
ATP levels were determined using an isocratic reverse-phase high-pressure liquid 
chromatography method described previously with slight modifications (Yang et al., 
2004).  Briefly, cells plated in 10 cm tissue culture plates were exposed to 1 mM 1,3-
DNB alone, or in the presence of 1 mM acetyl-carnitine (ALCAR) or 1 mM acetoacetate 
(AcAc).  At the following time points (6, 12, 24, and 36hr), plates were rinsed in D-PBS 
and immediately snap frozen in liquid N2.  ATP was acid-extracted with ice-cold 
perchloric acid (0.3M) containing EDTA (1 mM).  The plates were scraped, acid extracts 
were transferred to microcentrifuge tubes, and protein was pelleted by centrifugation at 
9000 x g for 5 min at 4 °C.  Protein pellets were saved for protein quantification.  Protein 
free extracts were neutralized with KOH and precipitated KClO4 was removed by 
centrifugation (9000 x g, 4°C).  Extracts were stored at -80°C until HPLC analysis was 
performed.  
 
ATP Quantification by High Pressure Liquid Chromatography (HPLC) 
Adenine nucleotides were separated by HPLC using a Waters HPLC system equipped 
with a dual λ-absorbance UV detector and an inline degasser.  Isocratic elution was 
performed on a Symmetry 300™ C-18 column (4.6 x 150 mm, 5 µm) at a flow rate of 0.6 
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ml/min and peak absorbance recorded at 206 nm.  The mobile phase consisted of 0.1 M 
ammonium dihydrogen phosphate with 1% methanol. ATP concentrations were 
calculated using peak height, which was determined to be directly proportional to ATP 
concentration when compared to ATP standards treated in the same manner as samples. 
 
Measurement of Extracellular Lactate Concentrations   
Extracellular lactate accumulation was determined by the lactate dehydrogenase method 
through monitoring the conversion of NAD to NADH at 340 nm as previously detailed 
with slight modification (Yang and Balcarcel, 2004).  Lactate assay reagent contained 0.2 
M glycine buffer (pH 9.2), 0.15 M hydrazine, and 10 mM NAD.  The reaction was 
started with the addition of lactate dehydrogenase (10 U) and the rate of conversion was 
monitored.  The rate of conversion is directly proportional to lactate concentration, which 
was determined using lactate standards.    
           
Cytochemical Determination of PDHc and KGDHc Activity.   
PDHc and KGDHc activity were determined by the quantitative cytochemical method as 
described by (Park et al., 2000), with slight modifications.  Briefly, cells treated in 6 well 
plates were rinsed with D-PBS twice and 1 ml of reaction buffer containing 50mM Tris-
HCl (pH 7.6), 1 mM MgCl2, 0.1mM CaCl2, 0.05 mM EDTA, 0.3 mM thiamine 
pyrophosphate, 0.5 µg/ml rotenone (dissolved in 100% ethanol; final ethanol 
concentration, 0.1%), 0.2% Triton X-100, 3.5% polyvinyl alcohol, 3mM pyruvate or α-
ketoglutarate, 3 mM NAD+, 0.75 mg/ml coenzyme A, 0.75 mM nitroblue tetrazolium 
(NBT), and 0.05 mM phenazine methosulfate (PMS) was added to the cells.  Both NBT 
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and PMS were added immediately before the reaction was initiated.  The reaction was 
allowed to proceed for 1 hr and stopped by washing the plates twice with D-PBS.  
Solubilization of reduced NBT was accomplished by the method previously described 
(Rook et al., 1985).  Unreduced NBT was rinsed away with methanol twice and allowed 
to air dry.  To the dried plates, 240 µl of 2 M KOH was added followed by the addition of 
280 µl of DMSO.  The contents of each well were mixed thoroughly by trituration and 
200 µl of solution from each well was transferred to a corresponding well of microtiter 
plate.  Absorbance was read at 630 nm.  Wells treated with reaction mixture minus 
pyruvate or α-ketoglutarate were used as blanks to account for non-specific reduction of 
NBT.   
       
SDS-PAGE and Western Blotting 
Total cellular protein was extracted with ice-cold cell lysis buffer consisting of Tris-HCl 
(50 mM, pH 7.4), NaCl (150mM), Triton X-100 (1% v/v), and protease and phosphatase 
inhibitor cocktails (0.1% v/v) (Sigma).  Cell lysates were snap frozen in liquid N2 and 
stored at -80 °C until protein quantification and SDS-PAGE.  Cellular debris was 
removed by centrifugation and protein concentration was determined by the 
Bicinchoninic acid method (Smith et al., 1985) using a commercial kit (Pierce) as 
described by the manufacturer.  Approximately 20 µg of protein was mixed with sample 
loading buffer containing β-mercaptoethanol and denatured at 100°C for 10 min.  The 
proteins and molecular weight standards were resolved on 4-20% Tris-glycine gels 
(Lonza) and electroblotted to PVDF membrane.  Membranes were blocked with non-fat 
milk (5% w/v) in Tris-buffered saline (pH 7.6) containing Tween-20 (1% v/v) (TBS-T).  
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After 30 min of blocking the membranes were probed with anti-lipoic acid (1:5000), and 
anti-E2 subunit of PDHc (1:2000) overnight at 4°C.  The membranes were washed with 
TBS-T followed by probing with an appropriate alkaline phosphatase conjugated 
secondary antibodies (1:10000).  The membranes were developed using an ECF detection 
system (Amersham Biosciences, Piscataway, NJ) and visualized on a FujiFilm laser 
imaging system.  
      
Oxidized Protein Detection with OXYBLOT™ 
Oxidative modification of proteins can result in carbonylation of amino acid side chains.  
Carbonylated proteins can be distinguished by derivatizing these carbonyls with 2,4-
dinitophenyl hydrazine (DNPH) and subsequent immunodetection with an antibody 
specific to the attached DNP moiety (Dalle-Donne et al., 2003).  Modified proteins were 
detected utilizing a commercial OXYBLOT™ kit (Chemicon, Temecula, CA) as detailed 
in the kit manual with slight modifications.   
Mitochondrial Protein Isolation 
Mitochondria protein was isolated from treated C6 glioma cells plated in T-75 tissue 
culture flasks, following the commercial protocol MITOISO1 from Sigma (St. Louis, 
MO) with slight modification.  Briefly, cells from 8 T-75 flasks were homogenized in 10 
volumes of BSA (2mg/ml) containing extraction buffer with a dounce glass homogenizer 
and Teflon pestle.  Extraction buffer consisted of 220 mM mannitol, 70 mM sucrose, 0.5 
mM EGTA, and 2 mM HEPES at a final pH of 7.4.  Intact mitochondria were pelleted by 
centrifugation (11,000g, 4°C, 10 min).  The pellet was then resuspended in extraction 
buffer and centrifuged again as before.  This step was repeated a second time.  The final 
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mitochondrial pellet was then resuspended in storage buffer consisting of 10 mM, 
HEPES, 250 mM sucrose, 1 mM ATP, 0.08 mM ADP, 5 mM sodium succinate, 2 mM 
K2HPO4, and 1mM DTT and protease inhibitor cocktail (Sigma, St. Louis, MO).  
Mitochondrial were lysed by repeated freeze thaw cycles and total mitochondrial protein 
was quantified by BCA as described earlier.   
Oxyblot Analysis 
Mitochondrial protein (20 µg) was denatured with 12% SDS and derivatized with 1X 
solution of dinitrophenylhydrazine.  The derivatized samples were separated by gel 
electrophoresis and electroblotted to PVDF membrane as described earlier.  The 
membranes were probed with anti-DNP (1:150) overnight at 4°C.  The membrane was 
then washed and probed with appropriate alkaline phosphatase conjugated secondary 




LDH release, extracellular lactate concentrations, ATP concentrations, and enzyme 
activity levels in control and treated cells were compared using ANOVA with Student t-
test for post hoc analysis (Prism version 2.0, Graph Pad Software, INC., San Diego, CA).  







Morphology and Cytotoxicity 
Changes in the morphology of C6 glioma cells were dose-dependent and included 
extensive and increasing vacuolation with accompanying nuclear and cytoplasmic 
swelling at 36 hrs of exposure (Fig. 3-1).  No morphological changes were observed in 
control cultures treated with DMSO.  Higher concentrations of 500 µM and 1 mM DNB 
produced significant cell shrinkage and debris suggesting cell death.  This was confirmed 
by measuring release of the cytosolic marker LDH.  Significant dose dependent increases 
in extracellular LDH occurred at both 500 µM and 1 mM (P<0.01) (Figure 3-2).  
Removal of glucose through dosing in glucose free media resulted in exacerbation of cell 
death at both high doses.  Additionally, The cytotoxic effects of 1,3-DNB were 
determined using the MTT reduction assay (Figure 3-3).  Dose-dependent inhibition of 
mitochondrial reducing potential occurred upon treatment of C6 gliomas with 1,3-DNB 
(10 µM – 2 mM) for 36 hours, with a calculated IC50 = 978 µM.  
 
Metabolic Status. 
 Significant accumulation of extracellular lactate was observed at 36 hours of 
exposure, beginning at the lowest dose employed of 100 µM 1,3-DNB and increased in a 
dose dependent manner with nearly a 2-fold increase at the highest concentration of 1 
mM (Figure 3-4).  Co-treatment of cultures with either acetoacetate or acetyl-carnitine  
(potential alternative fuel sources) attenuated lactate accumulation in culture medium at 
all concentrations of 1,3-DNB.  By contrast, equimolar levels of the non-acetylated 
analogue L-carnitine or free acetate did not affect lactate accumulation (Data not shown), 
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suggesting protective effects were attributable to the availability of the acetyl moiety.  In 
addition to increased extracellular lactate concentrations, cellular ATP levels were 
significantly diminished by exposure to 1,3-DNB (Figure 3-5).  Representative 
chromatographs of adenine nucleotides clearly show significant reduction in ATP levels 
with corresponding increases in both ADP and AMP concentrations at 24 hr of exposure 
to 1 mM 1,3-DNB and drastic depletion by 36 hr compared to vehicle control (Figure 3-
5a).   Figure 3-5b shows the time-dependent diminution of ATP concentrations, with 
significant reduction first detected after 12 hr of exposure.  Similar to lactate 
accumulation, co-treatment with both acetoacetate and acetyl-carnitine preserved cellular 
ATP content.   
   
PDHc and KGDHc activity.   
Cytochemical determination of PDHc and KGDHc residual activity was achieved 
through quantifying substrate specific reduction of nitroblue tetrazolium dye.  Prolonged 
exposure to 1,3-DNB (36hr) produced a concentration-dependent reduction in residual 
PDHc and KGDHc activities (Figure 3-6).  At 50µM, the lowest concentration employed, 
there was greater then 60% reduction in PDHc activity and approximately 95% inhibition 
at 1 mM compared to vehicle control.  KGDHc activity was less sensitive to the 
inhibitory affects of 1,3-DNB. IC50 for PDHc and KGDHc were approximately 45 µM 





Lipoic acid immunoreactivity.   
C6 glioma cells were exposed to either 1,3-DNB (50 µM – 500 µM) for 36 hours 
or to a constant concentration of 500 µM 1,3-DNB from a period of 30 minutes to 48 
hours.  In order to determine if modification of protein bound lipoic acid results after 
exposure to 1,3-DNB, an antibody that specifically recognizes unmodified lipoic acid 
was used.  Western blot analysis of total cellular protein, utilizing this lipoic acid 
antibody, reveals two distinct bands at approximately 70 and 55 kDa corresponding to the 
E2 components of the PDHc and KGDHc, respectively.  Exposure to 1,3-DNB resulted in 
loss of LA immunoreactivity of PDHc in both a time- and dose-dependent manner 
(Figure 3-7).  At 500 µM 1,3-DNB, significant reduction in PDHC-LA by 6 hours and 
complete loss by 12 hrs was observed.  Additionally, substantial reduction in LA 
immunoreactivity was observed at all concentrations of 1,3-DNB, at 36 hr of exposure 
with complete loss apparent at the dose of 50 µM 1,3-DNB.  Utilizing an antibody to the 
E2 subunit of PDHc, no significant loss in protein expression was observed (Figure 3-8a).  
1,3-DNB also affects KGDHc-LA immunoreactivity with significant loss at 6 hrs of 
exposure.  Residual immunoreactivity was observed at all time points following exposure 
to 1,3-DNB.  Loss of KGDHc-LA was not observed at 36 hours less than 100 µM 1,3-
DNB and residual bands can be seen up through the 500 µM dose. Co-treatment with 
various antioxidants (α-tocopherol, deferoximine) and thiol containing compounds (L-
cysteine, and DMSP) showed no significant attenuation of LA loss at 500 µM 1,3-DNB 
following 6 hrs of exposure (Figure 3-8b).  To further rule out the possibility of lipid 
peroxidation products being the cause for loss of LA immunoreactivity, total cellular 
protein was probed for 4-hydroxynonenal adducts (Figure 3-9a).  No substantial increases 
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in 4HNE adducts were observed with exposure to increasing concentrations of 1,3-DNB.  
Interestingly, treatment of C6 glioma cells with the classical PDHc inhibitors, arsenic 
trioxide and phenyl arsine oxide, at concentrations shown to completely inhibit PDHc did 
not result in decreased LA immunoreactivity (Figure 3-9b).           
 
Protein Oxidation.   
To determine if loss of LA immunoreactivity is a consequence of increased 
protein oxidation, OxyBlot analysis of mitochondrial protein samples was performed 
(Figure 3-10).  Exposure to 1 mM DNB for increasing time resulted in increased 
carbonylation of proteins corresponding to the molecular weights of both the PDHc and 
KGDHc E2 components with increases apparent by 45 minutes.  Protein oxidation of 
PDHc appears to be greater than that of KGDHc, evident by 24 hrs.  
 
Discussion 
Nitroaromatic induced CNS dysfunction is classified as part of a family of 
neurological disorders termed acute energy deprivation syndromes due to the similarities 
in lesion presentation as well as regional susceptibility differences (Cavanagh, 1993). The 
neuropathology observed in 1,3-DNB exposure most strikingly resembles that of diet 
induced thiamine deficiency resulting from a reduction in the activities of key thiamine 
dependent metabolic enzymes, the pyruvate dehydrogenase and α-ketoglutarate 
dehydrogenase complexes.  The significant increases in lactate and increased cerebral 
glucose utilization observed in both in vivo and in vitro 1,3-DNB exposure models, 
suggests a dysfunction in oxidative energy metabolism (Romero et al., 1991; Ray et al., 
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1994; Romero et al., 1995; Phelka et al., 2003).  The specific site where 1,3-DNB and 
other nitroaromatic compounds elicit their effects is not known, though studies have 
shown mitochondrial function to be adversely affected (Phelka et al., 2003; Tjalkens et 
al., 2003).  We set out to investigate the ability of this neurotoxic compound to impair 
key metabolic enzymes in intact cells as well as examine potential mechanisms of this 
impairment.  
 In the present study, C6 glioma cells were used as an astrocyte model to 
investigate possible mechanisms underling 1,3-DNB induced metabolic dysfunction.  
Exposure of C6 gliomas to 1,3-DNB resulted in similar morphological and biochemical 
changes that have been previously observed and reported in other models of 1,3-DNB 
susceptible CNS populations (Philbert et al., 1987; Romero et al., 1995).  1,3-DNB (500 
µM and 1 mM) elicited morphological changes including cellular swelling, and extensive 
vacuolization by 36 hours of exposure in cultures of C6 glioma cells (Figure 3-1) which 
is comparable to previous 1,3-DNB experiments performed in primary astrocyte cultures.  
Interestingly, similar structural changes were achieved at lower concentrations but this 
required a much longer time period, suggesting that the toxic mechanism potentially is 
initiated at lower dose levels but time is required to manifest into overt pathological 
changes.  This delay may be due to the need for sufficient biochemical changes to occur 
before observable structural changes are noticeable.   
 During 1,3-DNB intoxication, the metabolic status of C6 gliomas is compromised 
evidenced by dose-dependent increases in extracellular lactate concentrations (figure 3-
4), as well as depletion of ATP (figure 3-5).  Increased extracellular lactate is a common 
outcome in conditions where mitochondrial oxidative metabolism is compromised such 
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as hypoxia/ischemia, traumatic brain injury (Ringel et al., 2006), and genetic 
abnormalities of mitochondrial specific metabolic enzymes (Robinson, 2006). To 
maintain ATP levels in the absence of functional mitochondrial pathways, the cell must 
accelerate glycolytic production of ATP.  This would account for the increased glucose 
utilization observed in some cases of AEDS including 1,3-DNB intoxication (Romero et 
al., 1991; Ray et al., 1994; Romero et al., 1995).  During exaggerated glycolytic activity 
NAD stores are potentially depleted.  In order for glycolytically derived ATP production 
to proceed, NAD levels must be maintained due to the requirement for this cofactor by 
glyceraldehyde-3-phosphate dehydrogenase.  Normally, NADH is re-oxidized in the 
mitochondria but if this process is disrupted, NAD may be formed during anaerobic 
glycolysis through lactate dehydrogenase, which converts pyruvate to lactate.  This 
accumulation of lactate can have detrimental affects if not regulated quickly, mainly due 
to acidification of the extracellular and subsequently the intracellular environments.  
Acidosis-induced persistent cell swelling has been shown to occur in astrocytic C6 
glioma cells (Nabekura et al., 2003).  In line with the previous thought, it may require 
sufficient accumulation of extracellular lactate with a corresponding drop in extracellular 
pH, to manifest the morphological changes observed.    
 The ability of both acetoacetate and acetyl-carnitine (ALCAR) to protect cells 
from structural and biochemical changes during 1,3-DNB intoxication (Figure 3-1, 3-4 
and 3-5) further supports a defect in oxidative energy metabolism and more specifically 
PDHc.  Both acetoacetate (AcAc) and ALCAR have the potential to be converted to 
acetyl-CoA and subsequently can enter the TCA cycle.  The ketone body, acetoacetate, is 
an endogenously circulating substrate known to contribute to cerebral metabolism.  
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Under most normal conditions the primary fuel for the brain is glucose.  However, during 
many physiologic and pathologic situations including specific periods during postnatal 
development, starvation and ischemia, cerebral adaptation to ketone metabolism can 
occur (Edmond, 1992; Morris, 2005).  Direct administration of ketone bodies, as well as 
institution of ketogenic diets results in neuroprotection in numerous disorders, most 
relevant being pyruvate dehydrogenase complex deficiency.  Similarly, ALCAR can be 
converted to acetyl-CoA through the actions of acetylcarnitine-CoA transferase.  The 
protective effects of ALCAR have been demonstrated in models of ischemia and 
reperfusion in both cardiac and brain tissue (Rosenthal et al., 1992; Lesnefsky et al., 
2006).  The acetyl-CoA derived from acetoacetate and ALCAR potentially enter into 
oxidative energy metabolism effectively bypassing defective PDHc.  This would allow 
for ATP levels to be sustained and result in the reduction of glycolytic activity and 
consequently lactate production.  Both the reduction in extracellular lactate and 
maintenance of ATP level were observed upon co-administration of these metabolically 
active substrates with 1,3-DNB. 
 Though lactate accumulation and acidification of the extracellular environment 
maybe important in overall pathogenesis of 1,3-DNB neurotoxicity, it appears energetic 
status of the cell is the ultimate determinant of cell fate.  This is apparent through the 
dramatic increase in cell death as determined by LDH release in glucose free cultures 
(Figure 3-2).  Removal of glucose would prevent glycolytic ATP production and 
consequently reduce the amount of lactate produced.  If lactate concentrations are most 
important then removal of glucose should show protective effects against 1,3-DNB.  The 
2-fold increase in extracellular LDH levels in the absence of glucose suggests that C6 
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gliomas maintain enough ATP through oxidation of glucose to prevent substantial cell 
loss.  One alternative explanation is that C6 gliomas undergo apoptotic cell death in 
presence of glucose, which would not be quantifiable by LDH release.  Apoptotic cell 
death is an energy demanding process and if ATP levels are not sustained at high enough 
levels throughout the process, necrotic cell death maybe triggered.     
 Exposure of C6 glioma cells to 1,3-DNB resulted in the loss of both PDHc and 
KGDHc activity in a dose dependent manner (Figure 3-6).  Dramatic loss of PDHc 
activity was observed at the lowest concentration of 50 µM.  This dose level corresponds 
closely to the blood concentration of the threshold neuropathic dose of 25mg/kg in F344 
rats which was calculated to be 43 µM (Bailey et al., 1988).  This dose also was shown to 
be the threshold dose for increased glucose utilization in primary astrocytes (Romero et 
al., 1995).  There appears to be differential sensitivity, with PDHc being more susceptible 
to inhibition, demonstrated by a 5-fold difference in IC50 concentrations.  These 
complexes are very similar in structure and function and would be expected to respond 
similarly to 1,3-DNB.  Further investigation on potential differences amongst the two 
complexes that confers the discriminating affects of 1,3-DNB is needed. 
PDHc, like other α-keto acid dehydrogenase complexes, possesses a covalently 
bound lipoic acid on the E2 component of the complex.  The vicinal dithiol group of LA 
facilitates acetyl transfer from the hydroxyethyl-intermediate of the E1 bound thiamine 
pyrophosphate to coenzyme A.  Covalent modification of LA is a major mechanism for 
PDHc inhibition.  This is seen with mono- and bi-functional arsenicals, as well as strong 
electrophiles like the α,β-unsaturated aldehydes produced during lipid peroxidation 
(Stevenson et al., 1978; Patel and Korotchkina, 2002; Samikkannu et al., 2003).  Using 
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antibodies that specifically recognize the covalently bound lipoic acid moiety we 
investigated whether LA was potentially affected by 1,3-DNB.  Western blot analysis of 
protein from C6 glioma cells exposed to increasing concentrations of 1,3-DNB showed 
dose-dependent decreases in LA immunoreactivity (Figure 3-7).  In order to determine if 
reduced LA immunoreactivity was resultant from changes in protein expression of the E2 
component of PDHc, membranes were probed with an anti-E2 antibody, which showed 
no changes in expression level (Figure 3-8).  This data supports the conclusion that loss 
of LA immunoreactivity is due to modification of the antigenic sight on lipoic acid and 
not because of reduction in protein expression of the E2 component.  Modification of LA 
was also shown to be time dependent at the highest dose of 500 µM DNB with changes in 
immunoreactivity evident at the earliest time point of 6 hr and complete loss by 12 hrs 
(Figure 3-7).  Interestingly, when comparing the loss of LA with the activity of PDHc, we 
observe complete loss of LA immunoreactivity with 50 µM at 36hrs though 
approximately 40% residual PDHc activity remains.  This suggests that considerable loss 
of lipoic acid residues maybe required in order for substantial reduction in PDHc activity 
to occur.  Supporting this hypothesis is a study looking at the age-related increases in 
protein adduction of KGDHc by 4-hydroxynonenal (HNE) in rat heart (Moreau et al., 
2003).  HNE is a highly reactive lipid peroxidation product believed to modify lipoyl 
moieties in both KGDHc and PDHc.  The authors of this study found that a marked 
increased in adduction occurred in older rats without a corresponding drop in enzyme 
activity.  In fact, activity in older rats increased 1 fold compared to young rats.  The 
authors concluded that the amount of binding was at a low enough level not to 
significantly affect activity supporting the notion that these complexes may contain a 
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surplus of lipoic acid sites and that potentially a threshold level of sites must be modified 
before significant loss of activity is achieved.  Interestingly, there also appears to be a 
compensatory increase in catalytic efficiency in response to increased protein oxidation, 
with adjustments to Km towards the substrate α-ketoglutarate. 
Dysfunction of the pyruvate dehydrogenase complex has been reported in a host 
of neuropathogical states including ischemia/reperfusion injury and neurodegenerative 
diseases (Sheu et al., 1985; Butterworth and Besnard, 1990; Fukuchi et al., 1998).  In 
both situations, increased production of reactive oxygen species (ROS) have been 
implicated in disease progression.  This increased oxidative stress is proposed to underlie 
the loss of PDHc activity.  PDHc is highly sensitive to direct inactivation by hydroxyl 
radicals (Bogaert et al., 1994).  Indirectly, ROS can result in inactivation of PDHc 
through the initiation of lipid peroxidation and subsequent formation of highly reactive 
α,β-unsaturated aldehydes like, 4-hydroxy-nonenal and 2-propen-1-al (acrolein) 
(Humphries and Szweda, 1998; Pocernich and Butterfield, 2003). Both compounds have 
been shown to adversely affect PDHc activity potentially through binding of protein 
bound lipoic acid.   
  Bioactivation of nitroaromatic compounds is believed to be a necessary step in the 
cytotoxic mechanisms of several of these chemicals (O'Brien et al., 1990).  
Dinitrobenzenes, like many nitroaromatics, undergo nitroreduction as one of the main 
metabolizing pathways.  1,3-DNB undergoes 6-1e- reductions to the final product 3-
nitroaniline.  During this process, highly reactive intermediates may be formed which 
have the potential to further react with cellular macromolecules such as nucleic acids, 
lipids or proteins, effectively disrupting their functions.  One electron reduction of the 
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nitro group of 1,3-DNB produces a radical anion that in the presence of an aerobic 
environment has the potential to redox cycle.  This futile redox cycle results in increased 
production of superoxide anion and establishment of an oxidative stress environment.  
Evidence for this process has been shown in primary astrocyte cultures, where significant 
reduction in total glutathione (GSH) after 2 hours of exposure to 1,3-DNB, as well as an 
8-fold increase in superoxide levels after 1 hour of exposure (Ray et al., 1994).  
Alterations in GSH status were also shown to modulate susceptibility to 1,3-DNB 
induced neurotoxicity (Hu et al., 1999).  These studies support the hypothesis that 
oxidative stress is involved, at least in part, in the toxicity of 1,3-DNB.   
To investigate whether 1,3-DNB-mediated oxidative stress maybe responsible for 
the loss of LA immunoreactivity, protein carbonylation, an indicator of protein oxidation, 
was determined.  Time-dependent increases in carbonylation of proteins at the apparent 
molecular weights of the PDHc and KGDHc E2 components were observed (Figure 3-
10).  This suggests that oxidative modification of LA by carbonylation may be 
responsible for the apparent loss of LA immunoreactivity.  However, the addition of 
antioxidants and thiol containing compounds (trolox, deferoximine, cysteine and DMPS) 
showed no attenuation of LA loss implying that the loss of lipoic acid immunoreactivity 
may not be due to either protein oxidation by reactive oxygen species or to adduction by 
lipid peroxidation products.  Western blot analysis using an antibody specific to HNE 
showed no significant increases in HNE adducts of any proteins during 1,3-DNB 
exposure which strengthens the thought that lipid peroxidation products are not 
responsible for the loss of LA as well as the increased protein carbonylation observed (3-
9).  
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In addition to ROS production, highly reactive intermediates, including 
Nitrosonitrobenzene (NNB) and nitrophenylhydroylamine are formed during 
nitroaromatic metabolism.  These compounds are strong electrophiles that can react with 
nucleophilic centers of proteins such as thiols, histidinyl secondary amines, and primary 
amines leading to protein modification.  3-NNB was shown to react with biological 
thiols, specifically GSH (Ellis et al., 1992).  Likewise, 3-NNB may potentially react with 
reduced thiols of LA resulting in modification and loss of immunoreactivity.  The 
inability of both antioxidants and thiol containing compounds to protect against 1,3-DNB 
loss of LA may potentially be due to the inaccessibility of these compounds to the site of 
reactive intermediate production.  The E3 component (Lipoamide dehydrogenase) of α-
ketoacid dehydrogenase complexes oxidizes the reduced lipoic acid of E2 using the 
cofactor FAD.  This component was also shown to possess nitroreductase activity, 
catalyzing 1, 2 and 4 electron reductions of the nitro group (Tsai, 1987).  Nitrofuran 
reduction by lipoamide dehydrogenase resulted in redox-cycling and production of 
superoxide (Sreider et al., 1990).  1,3-DNB, which exclusively undergoes nitroreduction, 
is believed to be primarily metabolized in the mitochondria in seminiferous tubules 
resulting in depletion of mitochondrial GSH (Reeve et al., 2002).  The subcellular site of 
metabolism in other tissues has not been determined.  These studies all point to the 
potential for the reductive metabolism of 1,3-DNB to occur in the mitochondria by 
lipoamide dehydrogenase with possible production of either superoxide or reactive 
electrophiles occurring within its active site.  Complex geometry and consequential active 
site coupling within these enzyme systems could potentially allow for direct access of 
these reactive compounds to E2 bound lipoic acid and subsequent modification.  Since 
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their production is within the complex, anti-oxidants and thiol containing compounds 
may not be able to sequester these intermediates, which preclude their protective 
function.  
As with activity measurements, differential affects of 1,3-DNB on LA 
immunoreactivity and protein carbonylation were observed between the two complexes.  
PDHc was more sensitive than KGDHc with respect to both outcomes.  The presence of 
the additional protein, E3BP, may explain why these structurally related compounds are 
differentially inhibited by 1,3-DNB exposure.  E3BP, like the E2 component, possesses a 
lipoyl domain with a covalently bound LA.  E3BP is responsible for binding the E3 
component to the E2 structural core and is essential for the catalytic activity of the overall 
complex.  Its value is demonstrated by an 80 to 90 percent reduction in PDHc activity in 
those individuals who genetically lack E3BP (Brown et al., 2006).  New ultra-structural 
models suggest that the E2 lipoyl domains interact exclusively or at least preferentially 
with the E1 component, while the E3BP lipoyl domain interacts with the E3 (Smolle et 
al., 2006).  If this model were correct, the electron flow from reduced LA on the E2 to 
NAD+ would go through the E3BP-LA, supporting more then just a structural role for 
this component.  E3BP may allow for the reactive intermediates produced by the E3 
component to be efficiently transferred to the E2 bound lipoic acid.  This component is 
not present in KGDHc, which potentially reduces the ability of these intermediates to 
access the E2 bound LA.  The correlation between loss of LA, increases in protein 
oxidation and inhibition of activity all point to direct protein modification of PDHc as the 
most likely route for 1,3-DNB meditated inhibition.    
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In conclusion, 1,3-DNB results in metabolic impairment of the astrocyte-derived 
cell line, C6 glioma.  This metabolic disruption appears to be mediated by inhibition of 
PDHc potentially though modification of protein bound LA.  Though the data presented 
in this study suggests that reactive oxygen species, as well as lipid peroxidation products 
were not responsible for loss of LA immunoreactivity, the absence of evidence for direct 
adduction by 1,3-DNB or its reactive intermediates underscores the need for further 






































































Figure 3-1.  (A) Representative photomicrographs demonstrating dose dependent effects 
of 1,3-DNB (250 µM – 1 mM) exposure on the morphology of C6 gliomas (10X).  
Cellular swelling, extensive vacuolation and loss of cell monolayer occurs at 500 µM 1,3-
DNB.  The effects are greatly exaggerated at 1 mM with significant membrane blebbing 
and loss of cells. (B) Representative photomicrographs demonstrating the protective 
effects of acetoacetate (AcAc) (1 mM) on 1,3-DNB (500 µM) mediate morphological 
changes at 24 hr of exposure (20X).  Substantial reduction in cellular vacuolation and 
maintenance of cell monolayer is observed in co-treated cultures.  
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Figure 3-2.  Effects of 1,3-DNB on C6 glioma cell viability.  Cell death was assessed by 
measuring the release of the cytosolic maker lactate dehydrogenase (LDH).  Exposure of 
C6 gliomas to 500 µM and 1 mM 1,3-DNB results in significant increase in LDH release 
in the presence and absence of glucose.  Removal of glucose results in greater then a 2-
fold increase in LDH release.   Data are expressed as mean concentration +/- SE (N=4) of 
extracellular LDH (U/L).  (*) denotes significant difference (P<0.01) from non-treated 
controls. (a) denotes significant difference (P<0.01) from +Glucose.       
 





































Figure 3-3.  Effects 1,3-DNB on C6 glioma cell viability as assessed by MTT reduction.  
Dose dependent loss of mitochondrial reducing potential occurred at 36hrs after exposure 
to increasing concentration of 1,3-DNB (10 – 2000 µM).  Data is presented as the mean 
+/- SE of percent reduction compared to DMSO treated controls.  The IC50 value for 




























































Figure 3-4.  Determination of extracellular lactate accumulation in culture medium of C6 
glioma cells exposed to increasing concentrations of 1,3-DNB alone or co-treated with 
1,3-DNB and 1 mM acetyl-carnitine (ALCAR) or Acetoacetate (AcAc) for 36 hrs.  1,3-
DNB exposure results in a significant increase in extracellular lactate in a dose dependent 
manner and this increase was attenuated with co-treatment of both ALCAR and AcAc.  
Results are expressed as means +/- SE (n=4) from 3 different experiments.  (*) denotes 
significant difference from Cntrl (P<0.01) and (a) denotes significant difference between 























































Figure 3-5.  A) Representative chromatograms depicting time-dependent loss of 
intracellular ATP with concurrent increases in AMP. The HPLC retention times 
corresponding to the peaks of ATP, ADP, and AMP were 3.684, 4.108, and 5.382, 
respectively.  B) ATP depletion in C6 glioma cells treated with either 1 mM 1,3-DNB 
alone or co-treated with 1,3-DNB and 1 mM acetyl-carnitine (ALCA) for up to 36hrs.  
Significant reduction in ATP was first observed at 12hrs and continued to decline in a 
time dependent manner.   Results are expressed as means +/- SE (n=3).  (*) denotes 
significant difference from Cntrl (P<0.05) and (a) denotes significant difference between 




































Figure 3-6.  Dose dependent reduction in PDHc and KGDHc activities in C6 gliomas 
after 36hrs of exposure. Data expressed and % residual activity +/- SE as compared to 















































Figure 3-7.  A) Lipoic acid (LA) immunoreactivity of total cellular protein from C6 
gliomas exposed to either 500 µM 1,3-DNB for 6, 12, 24, and 48hr or 50, 100, 250, and 
500 µM for 36 hr. B) Graphical representation of mean pixel intensity ratios normalized 
to complex II expression.  1,3-DNB exposure results in substantial loss of both PDHc and 
KGDHc LA immunoreactivity at 6hr and complete loss at12hr.  At 36 hr, dose dependent 
loss of LA immunoreactivity was observed.  KGDHc-LA appears to be less sensitive to 
loss compared to PDHc-LA with substantial loss of KGDHc-LA only occurring at 250 



























































Figure 3-8.  Western blot analysis of the E2 component of PDHc.  No significant 
changes in E2 expression were observed with increasing concentrations of 1,3-DNB (10-
1000µM (A).  Effects of anti-oxidants, α-tocopherol (α-TOC), and deferoximine (Def) as 
well as thiol containing compounds, L-cysteine (L-CYS) and 2,3-dimercapto-1-
propanesulfonic acid (DMPS) on 1,3-DNB induced loss of lipoic acid immunoreactiviy.  






































































Figure 3-9. (A) Determination of 4-hydroxynonenal adducts of total cellular protein from 
C6 glioma cells dosed with increasing concentrations of 1,3-DNB (50 – 1000 µM).  No 
significant changes were observed.  (B) Effects of the arsenical compounds, phenylarsine 
oxide (PAO) and arsenic trioxide (AO), on LA immunoreactivity in C6 glioma cells.  
Exposure to PAO (10 µM) and AO (100 µM) for 4 and 24 hr, showed no effects on 

































































Figure 3-10. A) Lipoic acid immunoreactivity of total cellular protein from C6 gliomas 
dosed with 1,3-DNB (1 mM) for 45min, 6hr, 12hr, and 24hr.  Loss of LA 
immunoreactivity was apparent at the earliest time point of 45 min and complete loss 
occurred by 24 hrs.  Corresponding Oxyblot analysis showed time dependent increase in 
protein carbonylation of bands corresponding to the positions of PDHc and KGDHc E2 
components.  B)  Graphical representation of mean pixel intensity ratios normalized to 
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ASTROCYTE AND NEURONAL INTERACTIONS IN AN IN VITRO MODEL 




1,3-Dinitrobenzene is one of several metabolic disruptors known to induce 
neuropathology characteristic of a class of diseases termed the acute energy deprivation 
syndromes (AEDS).  A hallmark of AEDS is the initial sparing of neurons, with neuronal 
damage occurring secondary to edema and loss of astrocytes.  The ability of astrocytes to 
modulate cytotoxic responses of neurons is well established.  The current study was 
undertaken to investigate the ability of the astrocyte cell model DI TNC-1 to protect SH-
SY5Y neuroblastomas during metabolic impairment induced by 1,3-DNB.  SH-SY5Y 
cells, in single culture, showed substantial cytotoxicity upon exposure to 1,3-DNB (500 
µM, 24hr), which included morphological changes and loss of mitochondrial reducing 
potential.  Both cytotoxic outcomes were attenuated in co-cultures.  1,3-DNB was also 
shown to induce cell death as assessed by caspase-3 activation.  The amount of cleaved 
caspase-3 in SH-SY5Y cells was significantly reduced, in the presence of DI TNC-1.  
Interestingly, the pre-treatment with the A1 adenosine receptor antagonist, DPCPX, 
resulted in increased caspase-3 activation even in the presence of DI TNC-1 cells, 
suggesting the involvement of purine signaling pathways in the cytoprotection observed.  
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Treatment of DI TNC-1 cells with 1,3-DNB resulted in increased extracellular 
adenosine, as well as AMP levels.  This increase may activate adenosine receptors, which 
are known to mediate neuroprotection in the CNS during numerous neuropathological 
conditions (Dunwiddie and Masino, 2001; Kochanek et al., 2005; Stone, 2005).  
Activation of adenosine receptors resulted in both reduction of SH-SY5Y excitability, 
determined through blockage of KCl-induced calcium waves, as well as induction of 
phospho-activation of ERK (1/2) and subsequent activation of the pro-survival protein 
BAD.  Further investigation into the complex interaction between neurons and astrocytes 
is needed and may lend some insight into the mechanisms of regional and cell specific 
sensitivity in AEDS.         
 
Introduction 
First being described as strictly structural scaffolding or glue, astrocytes have 
until recently been thought of as purely auxiliary components in the nervous system, the 
original belief being that astrocyte functions were restricted to passive maintenance of the 
extracellular environment.  Recently, knowledge of the metabolic and trophic functions 
of astrocytes has evolved tremendously.  One of the most important discoveries that 
reinvigorated interest in astrocytes was the observation of astrocytic Ca2+ excitability.  
This finding, coupled to release of “gliotransmitters” and the presence of numerous 
metabotropic receptors, suggested that astrocytes are in fact capable of active 
communication with their neighbors (Cornell-Bell et al., 1990; Charles et al., 1991).  
Astrocytes are found between neuronal synapses and the vasculature.  This positioning, 
together with active signaling machinery, supports a potential role of astrocytes in 
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regulating both synaptic transmission, as well as neurovascular coupling (Haydon and 
Carmignoto, 2006).  The continued uncovering of new and diverse functions of astroglia 
have led to the belief that these cells play critical roles in almost all aspects of 
neurophysiology, and maybe more importantly, are major determinants of neurological 
dysfunction. 
1,3-Dinitrobenzene (1,3-DNB), an important industrial intermediate in the 
production of numerous commercial products, has been shown to be glio-toxic.  
Prolonged or repeated exposure of rats to this nitroaromatic compound produces a 
distinct bilaterally symmetrical lesion, which is gliovascular in origin with the astrocytic 
and vascular components primarily affected (Philbert et al., 1987; Ray et al., 1994; 
Romero et al., 1995).  Neuronal damage arises secondary to edema resultant from 
vascular compromise and loss of astrocytes.  The increased sensitivity of astrocytes and 
the initial sparing of neurons, in 1,3-DNB exposures, is somewhat of a surprising 
outcome.  It has been established, through various in vitro and in vivo studies, that this 
neurotoxic compound elicits CNS damage, at least in part, through disruption of energy 
metabolism (Ray et al., 1992; Romero et al., 1995; Romero et al., 1996; Holton et al., 
1997).  Active neurons are presumably more metabolically demanding compared to their 
glial counterparts and accordingly are expected to be more susceptible to metabolic 
impairment elicited by this chemical.  Additionally, astroglia are exclusively responsible 
for formation of glycogen with enzymes involved in gluconeogenesis and glycogenolysis 
solely being expressed in astrocytes (Brown and Ransom, 2007).  The availability of this 
repository energy substrate, though present at low levels, potentially allows for 
maintenance of ATP concentrations in astrocytes under conditions of diminished energy 
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production, such as aglycemia (Swanson and Choi, 1993; Brown and Ransom, 2007).  
Oxidative stress also appears to play a significant role in the pathogenesis of 1,3-DNB-
mediated encephalopathy (Ray et al., 1994; Hu et al., 1999).  Neurons are generally 
thought to have lower antioxidant capacity compared to astrocytes, again suggesting that 
this cell type should be more sensitive to 1,3-DNB cytotoxicity (Dringen et al., 1999a).  
Though it may be possible that 1,3-DNB selectively targets astrocytes by a yet 
undetermined mechanism, one alternative explanation for cell specific differential 
sensitivity is the ability of astrocytes to potentially shield neurons through intercellular 
signaling or trophic support.  
In addition to a trophic role, astrocytes are also able to influence both neuronal 
and endothelial cell function through active communication utilizing astrocyte derived 
intercellular signaling molecules, termed gliotransmitters (Newman, 2003; Zhang and 
Haydon, 2005).  One potential signaling pathway believed to be involved in intercellular 
communication, in the CNS, is purinergic neurotransmission.  The extracellular action of 
purines as potential signaling molecules was first proposed in the late 20’ s, with the 
description of the potent actions of the purines, ATP and adenosine, in the heart (Drury 
and Szent-Gyorgyi, 1929).  Their role in the CNS was later cemented by Burnstock and 
colleagues (Burnstock, 1972). 
Adenosine, a ubiquitous purine nucleoside produced from the hydrolysis of ATP, 
is a potent modulator of many physiological functions through the activation of four 
specific adenosine receptors  (A1AR, A2aAR, A2bAR, and A3AR) (Fredholm et al., 2000).  
The most abundant of these receptors, the A1AR, have long been known to mediate 
neuroprotection in pathological conditions (Dunwiddie and Masino, 2001). Under 
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conditions of diminished energy production extracellular concentrations of adenosine 
dramatically increase resulting in activation of G-protein coupled metabotropic receptors 
in the efforts to reduce neuronal excitability through hyperpolarization and reduction of 
neurotransmitter release.  The activation of this receptor, in effect, silences the neurons to 
shield them during times of energy deprivation.  
In the present study, the astrocyte and neuronal cell lines, DI TNC-1 and SH-
SY5Y neuroblastomas, were used as an in vitro model of 1,3-dinitrobenzene-induced 
encephalopathy, to investigate the cell specific sensitivity to this compound, as well as 
the potential for astrocytes to protect neurons from cytotoxicity.  The role of adenosine 
receptor signaling in cellular communication between these cell types was also examined. 
  
Materials and Methods 
Cell Culture 
The astrocytic cell line DI TNC-1 obtained from American Type Culture Collection 
(ATCC) was employed in this study as an astrocyte model.  Originally established 
through targeted oncogenesis (Radany et al., 1992), these cells show similar 
characteristics to mature differentiated primary type 1 astrocytes, including substantial 
glial fibrillary acidic protein (GFAP) expression, high affinity uptake mechanism for 
GABA, and the ability to promote neurite outgrowth.  The neuronal model used in this 
study was the human SH-SH-SY5Y neuroblastoma cell line also obtained from ATCC.  
Both cell lines were maintained at 37°C under an atmosphere of 5% CO2 / 95% air (v/v) 
in Dulbecco’s modified eagles medium (DMEM; Gibco) supplemented with 10% fetal 
bovine serum and 1 x antibiotics (Penicillin, Streptomyosin, and Neomycin; Gibco).  
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Cells were subcultured using 0.25% trypsin and used 48 hr after plating.  Prior to 
treatment, cells were rinsed with Dulbecco’s phosphate buffered saline (D-PBS) and all 
treatments were performed in serum free DMEM.  For co-culturing experiments, 
transwell-clear permeable supports (Corning) were used, where SH-SY5Y 
neuroblastomas were plated in the wells and the DI TNC-1 were plated in the supports.  




SH-SY5Y and DI TNC-1 cells plated in 6 well plates were dosed with DMSO, 500 µM 
1,3-DNB, or 1 mM 1,3-DNB for 24 hr.  For co-culture experiments, both the wells and 
the supports were dosed with equal amounts.  After exposure, plates were then washed 
twice with D-PBS and phase-contrast light microscopy was performed using an Olympus 
CKX41 inverted microscope equipped with a Spot Insight QE digital CCD camera at 
20X magnification.   
Mitochondrial reducing potential  
Cytotoxic effects of 1,3-DNB on SH-SY5Y neuroblastomas alone and in co-culture were 
determined by monitoring the reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) as described (Mosmann, 1983).  The yellow, soluble 
tetrazolium dye is metabolically reduced to a purple, water-insoluble formazan, which is 
detected by a spectrophotometer.  Cells plated in a 6 well plates were dosed with 
increasing concentrations of 1,3-DNB (10 µM – 1000 µM).  After exposure, wells were 
rinsed with D-PBS and MTT assay solution (1 mg/ml in DMEM) was added to each well 
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and allowed to incubate for 2 h at 37°C.  MTT solution was then aspirated and 500 µl of 
DMSO was added to dissolve the formazan dye.  After 30 min incubation with vigorous 
mixing, absorbance was determined at 550 nm.  Mean absorbance values were compared 
to vehicle control and IC50 values were determined by fitting data to a sigmoidal dose-
response equation using Prism software (Graph Pad Software, Inc., San Diego, Ca). 
 
Intracellular Calcium Imaging by confocal microscopy 
Calcium wave images were acquired using an Olympus DSU confocal imaging system, 
consisting of an Olympus IX81 inverted microscope equipped with the disk scanning unit 
(DSU) and a ORCA-ER cooled charge-coupled device camera (Hammamatsu Photonics, 
Hamamatsu City, Japan).  SH-SY5Y neuroblastoma cells were plated onto 22 mm glass 
round coverslips and allowed to attach and recover for 48 hrs.  Cells were then incubated 
for 45 min with the Ca2+ indicator dye FURA-2/AM (3 µM) (Molecular Probes, Eugene, 
OR, USA) in sodium-ringer’s solution consisting of: NaCl (137 mM), KCl (5 mM), 
K2HPO4 (0.44 mM), NaHCO3 (4.2 mM), MgCl2 (1.2 mM), HEPES (20 mM), CaCl2 (1 
mM), glucose (10 mM), and adjusted to pH 7.4 with NaOH.  After incubation, cells were 
rinsed twice with sodium-ringer’s solution and cells were then incubated for 1 hr in order 
for the dye to de-esterify.  Coverslips were then mounted in an Attofluor® cell chamber 
(Invitrogen, Carlsbad, CA) and placed on a heated stage set at 37°C.  Baseline images of 
Fura-2 fluorescence at 340 nm were recorded for 1 min (1 image / 10 sec) prior to 
induction of the calcium wave through depolarization by KCl (25 mM).  Calcium wave 
propagation was monitored for 3 min.      
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Determination of Extracellular Adenyl Purines 
Extracellular concentrations of adenyl purines including; ATP, ADP, AMP, and 
adenosine, were determined through separation by high performance liquid 
chromatography with fluorescence derivatization as previously described (Katayama et 
al., 2001). 
Derivatization Conditions 
Culture media from DI TNC-1 cells treated with 1,3-DNB, containing adenyl purines 
(100 µl) were first clarified by centrifugation (3000 x g for 5 min at 4°C) followed by 
derivatization for 30 min at 80°C with 4.0 M 2-chloroacetaldehyde in 1.0 M acetate 
buffer (pH 4.5; 100 µl).  After derivatization, 10 µl of the reaction solution was injected 
into the HPLC apparatus.   
Chromatography conditions 
Adenyl purines were determined by separation on a Waters Alliance® HPLC.  Isocratic 
elution was performed on an Xbridge C18 column (4.6mm x 100mm, 3.5µm) at a flow 
rate of 0.8 ml/min.  Fluorescent detection of derivatized adenyl purines was performed 
with excitation wavelength at 280 nm and emission wavelength at 420 nm.  The mobile 
phase consisted of 0.1M K2HPO4, 0.05 citric acid, pH: 4.5 with 3% methanol.   
 
SDS-PAGE and Western Blotting 
SH-SY5Y cells plated in 6 well tissue culture dishes were exposed to 1,3-DNB (500 µM) 
for 24 hr.  The plates were washed with D-PBS twice and total cellular protein was 
extracted with ice-cold cell lysis buffer consisting of Tris-HCl (50 mM, pH 7.4), NaCl 
(150mM), Triton X-100 (1% v/v), and protease and phosphatase inhibitor cocktails (0.1% 
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v/v) (Sigma).  Cell lysates were snap frozen in liquid N2 and stored at -80 °C until protein 
quantification and SDS-PAGE.  Cellular debris was removed by centrifugation and 
protein concentration was determined by the Bicinchoninic acid method (Smith et al., 
1985) using a commercial kit (Pierce) as described by the manufacturer.  Approximately 
20 µg of protein was mixed with sample loading buffer containing β-mercaptoethanol 
and SDS and denatured at 100°C for 10 min.  The proteins and molecular weight 
standards were resolved on 4-20% Tris-glycine gels (Lonza) and electroblotted to PVDF 
membrane.  Membranes were blocked with non-fat milk (5% w/v) in Tris-buffered saline 
(pH 7.6) containing Tween-20 (1% v/v) (TBS-T).  After 30 min of blocking, the 
membranes were probed with either anti-cleaved-CASPASE-3 (1:5000; Cell Signaling), 
anti-phospho-ERK1/2 (1:5000; Sigma), or anti-phospho-BAD (1:5000; Cell Signaling), 
at 4°C overnight.  The membranes were washed with TBS-T followed by probing with an 
appropriate alkaline phosphatase conjugated secondary antibodies (1:10000).  The 
membranes were developed using an ECF detection system (Amersham Biosciences) and 
visualized on a FujiFilm laser imaging system.  
 
RESULTS 
Differential sensitivity of SH-SY5Y and DI TNC-1 cells with exposure to 1,3-DNB 
Exposure of both SH-SY5Y and DI TNC-1 cells to either 500 µM or 1 mM 1,3-DNB for 
24 hr resulted in significant morphological changes with SH-SY5Y being more sensitive 
(Figure 4-1a).  At 500 µM 1,3-DNB, DI TNC-1 cells showed classical changes in 
morphology including cellular swelling and extensive vaculoation.  Loss of cell 
monolayer was also apparent at this dose.  With the higher dose of 1 mM, exaggerated 
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swelling and vacuolation continued with the presence of cell debris indicating cell loss.  
SH-SY5Y cells showed substantial cytotoxicity with the balling of cells at the 500 µM 
dose and at 1 mM cell loss was greatly increased.   
 
Protection of SH-SY5Y through co-culturing with the DI TNC-1 cell line 
Co-culturing of SH-SY5Y with DI TNC-1 cells greatly diminished the cytotoxicity 
incurred upon exposure to 1,3-DNB (500 µM, and 1 mM) for 24 hr (figure 4-1b).  The 
morphological changes that resulted with 500 µM are completely attenuated.  Though 
protection was noticeable at the 1 mM dose, cytotoxic changes were still apparent, 
including cell shrinkage and balling.  The ability of DI TNC-1 cells to protect SH-SY5Y 
cells from toxicity was confirmed by monitoring mitochondrial reducing potential (Figure 
4-2).  1,3-DNB (10 µM – 1 mM) induced dose-dependent diminution of the cells 
reducing potential (P < 0.01) as determined by MTT reduction assay.  In contrast, co-
culturing SH-SY5Y cells with the astrocytic DI TNC-1 cells showed significant (P < 
0.01) attenuation of reduction potential loss.  
 
Co-culturing reduces the induction of cell death by 1,3-DNB 
The ability of 1,3-DNB to induce cell death in SH-SY5Y neuroblastoma cells was 
determined through examining caspase-3 activation (Figure 4-3).  Exposure to 500 µM 
1,3-DNB for 24 hr resulted in the cleavage of caspase-3 evident by detection of the 17 
and 19 KDa cleavage products.  Co-culturing SH-SY5Y cells with DI TNC-1 cells 
resulted in a significant reduction of detected cleaved caspase-3 fragments.  Treatment of 
SH-SY5Y cells with the A1 adenosine receptor antagonist, 8-cyclopentyl-1,3-
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dipropylxanthine (DPCPX), reversed the protection afforded by co-culturing, resulting in 
greater caspase-3 cleavage.  DPCPX alone appeared to result in slight induction of 
caspase-3 activation. 
 
Induction of cell survival pathways in SH-SY5Ys through activation of A1 adenosine 
receptors  
Activation of A1 adenosine receptors by the specific agonist, R-phenylisopropyladenosine 
(R-PIA) resulted in the phosphorylation of ERK (1/2), with peak expression being 
observed at 1 hr.  ERK (1/2) expression trailed off at 2 hours, and returned to basal levels 
by 4 hours (Figure 4-4).  Subsequent to ERK phosphorylation, upregulation of phospho-
BAD occured at 2 hr with peak expression at 4 hr.     
 
Effects of adenosine on KCl induced Ca2+ wave propagation. 
Addition of 25 mM KCl induced the propagation of an intense calcium wave (Figure 4-
5).  Treatment of SH-SY5Y cells with adenosine (5 nM, 20 min) prior to KCl 
depolarization delayed the induction of the calcium wave by approximately 30 sec, as 
well as suppressed the overall magnitude.  Pre-treatment with either the A1 specific 
adenosine receptor antagonist, DPCPX (250 nM, 30 min) or the broad-spectrum 
antagonist, theophyilline (10 µM, 30 min) prior to adenosine treatment, prevented the 
calcium wave suppression.  The A1 specific antagonist appeared to be more efficient at 




1,3-DNB mediated increases in extracellular AMP and adenosine. 
Treatment of DI TNC-1 cells with 1,3-DNB (500 µM) for 24 hr resulted in increased 





  1,3-Dinitrobenzene is one of several metabolic disruptors known to induce 
neuropathology characteristic of a class of diseases termed the acute energy deprivation 
syndromes (Cavanagh, 1993).  AEDS produce focal, glio-vascular lesions, in highly 
conserved brainstem regions, consistent with their high metabolic activity.  A hallmark of 
AEDS is the initial sparing of neurons, with neuronal damage occurring secondary to 
edema and loss of astrocytes (Philbert et al., 1987).  Metabolic impairment and induction 
of oxidative stress are key components to the pathogenesis of AEDS, making the 
observation that neurons are relatively insensitive to 1,3-DNB and other inducers of acute 
energy deprivation surprising.  Compared to their glial counterparts, neurons are believed 
to be more metabolically dependent on available ATP pools and less competent in 
dealing with oxidative stress, two characteristics that should predispose neurons to injury 
(Dringen et al., 1999a; Dienel and Hertz, 2005).  Though there is the potential for 1,3-
DNB to specifically target astrocytes over neurons, by a yet undetermined mechanism, it 
is more likely that the interrelationship of these two cell types determines their fate. 
  Astrocytes form intimate relationships with both neuronal and endothelial 
components in the CNS.  These relationships allow astrocytes to play an extremely 
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important role in cerebral function, homeostasis, as well as modulate toxicity.  Astrocyte 
functions include the regulation of extracellular environment through ion buffering and 
removal of the potentially toxic neurotransmitters, as well as facilitation and maintenance 
of both blood brain barrier (BBB) integrity and neuronal synaptic transmission (Hertz et 
al., 1999; Haydon and Carmignoto, 2006).  The demise of astrocytes would result in the 
breakdown of astrocyte/neuronal and astrocyte/endothelial interactions and ultimately 
produce both neuronal and vascular dysfunction. 
In the present study, the ability of astrocytes, to modulate the toxic responses of 
neurons in 1,3-DNB exposure was investigated using the cell models, DI TNC-1 and SH-
SY5Y neuroblastoma.  Comparing the effects of 1,3-DNB on the two cell types reveals 
that the neuronal cell line, SH-SY5Y is more susceptible to 1,3-DNB toxicity compared 
to astrocyte-derived DI TNC-1 cells.  This is contradictory to the in vivo situation where 
astrocytes are more sensitive to the pathological effects of 1,3-DNB.  This difference 
between in vivo and in vitro outcomes supports a role for intercellular relationships in 
influencing susceptibility to 1,3-DNB.   
Co-culturing DI TNC-1 cells with SH-SY5Y neuroblastoma cells significantly 
protected SH-SY5Y cells from both morphological and biochemical changes induced by 
24 hr exposure to 500 µM 1,3-DNB.  Numerous studies have established the ability of 
astrocytes to modulate cytotoxic responses of neuronal cells, in vitro, upon either 
treatment with astrocyte-conditioned media or through co-culturing systems.  In a study 
on rotenone toxicity, astrocyte-conditioned media protected MN9D neuronal cells from 
rotenone-induced oxidative stress and loss of cell viability (Cao et al., 2007).  Astrocytes 
were also shown to completely attenuate neuronal cell death resultant from thiamine 
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deficient culturing conditions (Park et al., 2001).  The ability of astrocytes to protect 
neurons potentially is due the supply of many factors including metabolic substrates, 
growth factors and cytokines, as well as the building blocks for neuronal oxidative stress 
defense.  Since metabolic disruption and oxidative stress both occur in 1,3-DNB 
intoxication it is possible that DI TNC-1 cells elicit their protection by one these 
mechanisms.   
Previous research has established that increased lactate production with release 
into the extracellular environment occurs during 1,3-DNB exposure in susceptible 
regions of the brain (Ray et al., 1994; Romero et al., 1995; Phelka et al., 2003).  This 
finding was also confirmed using C6 glioma cells as a model for astrocytes (Chapter 3).  
Though, lactic acidosis is a common event during disruption of aerobic energy 
metabolism and is believed to be related to disease progression, it has been proposed that 
increased lactate production is a compensatory action, by astrocytes, in order to supply 
metabolically deprived neurons with an alternative energy source (Schurr, 2006).  This 
notion is some what controversial but recent evidence suggests that neurons are capable 
of metabolizing lactate as an alternative carbon source, allowing for the maintenance of 
energy charge (Deitmer, 2000).   
Reductive metabolism of 1,3-DNB, in an aerobic environment, has the potential 
to produce reactive oxygen species through futile redox cycling.  The establishment of an 
oxidative stress environment during 1,3-DNB exposures has been confirmed with the 
increased levels of superoxide and depletion of reduced glutathione (Ray et al., 1994; 
Tjalkens et al., 2000).  The ability of astrocytes to regulate the antioxidant potential of 
neurons has occurs through release of ascorbate and subsequent uptake of 
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dehydroascorbate, as well as the supply of glutathione precursors, including cysteine and 
the dipeptides CysGly and γGluCys (Dringen et al., 1999b; Swanson et al., 2004).  The 
induction of neuronal antioxidant defense may also be a key mechanism underlying 
protection of SH-SY5Y in co-culturing with DI TNC-1               
In addition to the nutritive responses, astrocytes may potentially limit neuronal 
cytotoxicity through regulation of neuronal excitability, and in doing so reduce neuronal 
metabolic demand during times of energy crisis.  It is well established that adenosine, a 
ubiquitous purine nucleoside produced from the hydrolysis of ATP, acts as potent and 
critical modulator of several physiological functions in various systems, particularly 
those of excitable tissues such as cardiac and brain (Dunwiddie and Masino, 2001).  This 
important signaling molecule mediates its actions through activation of specific cell 
surface purinergic receptors termed the adenosine receptors.  There has been a recent 
expansion of interest in adenosine receptors due to the therapeutic prospect these 
receptors may hold in various pathological conditions including diabetes, epilepsy, 
cancer, neurodegeneration, cardiovascular disease and stroke (Williams and Jarvis, 2000; 
Stone, 2005).  
It is plausible, that in the presence of 1,3-DNB, where ATP production is 
dramatically hampered, a condition reminiscent of ischemia/hypoxia, similar 
compensatory actions take place.  The ability of the A1 specific adenosine receptor 
antagonist, DPCPX, to reverse the protective effects of DI TNC-1 with respect to 1,3-
DNB mediated induction of cell death in SH-SY5Y neuroblastomas, supports the 
potential role of adenosine receptors in the protection elicited by co-culturing.  The 
observation that DPCPX alone increased caspase-3 cleavage suggests a basal tonic 
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activation of adenosine receptors may occur during physiological conditions.  This is 
supported with the treatment of SH-SY5Y cells with adenosine deaminase, which breaks 
down adenosine.  Treatment with adenosine deaminase resulted in the reduction of basal 
phospho-ERK expression in SH-SY5Y.  Adenosine was also shown to reduce KCl 
mediated depolarization of SH-SY5Y excitability.  Upon addition of adenosine, KCl-
mediated calcium waves were not only delayed but overall magnitude was diminished.  
This response, mediated by adenosine, was due to activation of AR’s since almost 
complete restoration of neuronal excitability was achieved by the non-specific AR 
antagonist theophyilline.  Use of the A1AR specific antagonist, DPCPX, indicates 
activation of the A1AR receptor as responsible for neuronal silencing.  Depression of 
neuronal activity facilitates neuroprotection through counteracting release of excitotoxic 
neurotransmitters and continued membrane depolarization by activiation ionotropic 
glutamate receptors (Rudolphi et al., 1992).    
Under basal conditions, extracellular concentrations of adenosine have been 
reported to be in the nanomolar range but upon establishment of a mismatch between 
energy expenditure and supply, as seen in conditions of increased metabolic activity or in 
cases of hypoxia or ischemia, the extracellular levels of adenosine dramatically increase 
(Phillis, 1989).  Peak adenosine levels on the order of 3 µM have been recorded in the 
striatum of rats following 24 hr of focal ischemia induced by middle cerebral artery 
occlusion (Melani et al., 1999).  Exposure of the astrocyte-derived cell line DI TNC-1 to 
1,3-DNB resulted in significant increases in extracellular adenosine and AMP.  Though 
only nanomolar levels of adenosine were achieved upon treatment with 1,3-DNB this 
level would still be sufficiently high in order for activation of the A1AR (Williams and 
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Jarvis, 2000; Stone, 2005).  Extracellular adenosine can either be produce through direct 
release of intracellular adenosine or release of adenine nucleotides with subsequent 
metabolism by ecto-nucleotidases present on the plasma membrane (Martin et al., 2007).  
The substantial increase in extracellular AMP levels upon treatment with 1,3-DNB 
maybe due to a potential lack of ecto-nucleotidase expression in this cell type.  C6 
gliomas, another astrocyte-derived cell, do not release adenosine upon ischemic 
conditions due to the absence of AMP-preferring 5’-nucleotidase expression (Parkinson 
et al., 2006).  Expression profiles for adenine nucleotide metabolizing enzymes are 
needed for the DI TNC-1 cell line.  Alternatively, adenosine is quickly metabolized by 
adenosine deaminase, which may also be why extracellular adenosine levels were not 
substantially increased.  
 Increased extracellular adenosine levels results in activation of AR, followed by 
induction of suppressive signaling pathways.  These pathways result in compensatory 
actions such as vasodilation, cessation of neurotransmission, and diminution in cellular 
activity giving adenosine the distinction of a retaliatory signaling molecule (Yoon and 
Rothman, 1991).  With the release of adenosine, the astrocyte, in a sense, strives to 
protect the functional neurological component, the neuron, through activation of complex 
pro-survival signaling cascades. The biochemical pathways involved in adenosine’s 
ability to modulate cellular processes, in this perceived cell preservation, are vast, and not 
completely known. Like other G-protein coupled receptors, AR’s regulate intracellular 
cyclic AMP levels through either activation (A2a and A2b) or inhibition (A1 and A3) of 
adenylyl cyclase.  Cyclic AMP is an important 2nd messenger involved in many aspects 
of cellular processes including glucose mobilization from glycogen, activation of 
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transcription factors, regulation of cAMP-gated ion channels and stimulation of specific 
protein kinases (i.e. protein kinase A) (Liu and Simon, 1996).  
 Adenosine receptor activation has also been shown to signal through the 
mitogen-activated protein kinases (MAPK) (Schulte and Fredholm, 2003).  MAPKs are a 
diverse and well-conserved protein family of proline-directed serine/threonine kinases 
that have been described to control an extensive array of functions including, but not 
limited to, cell cycle progression, proliferation, and differentiation.  The MAPK family is 
subdivided into three main groups, the stress activated protein kinases (SAPK), the c-jun 
N-terminal kinases (JNK) and the most widely studied, extracellular signal-regulated 
protein kinases (ERK).  Activation of MAPK leads to phosphorylation of numerous 
transcriptional factors as well as various other proteins including those involved in 
regulating cell death (i.e. Bcl-2) (Breitschopf et al., 2000).  
The Bcl-2 family proteins have been implicated in the control of cellular 
sensitivity to endogenous and exogenous stresses.  They are believed to regulate the  
mitochondrial permeability transition (MPT) through intimate interactions with a multi-
protein pore (Lemasters et al., 1997).  MPT is one initiator of apoptotic cell death 
pathways.  Both anti- (Bcl-2, Bcl-xl) and pro- (Bax, Bid, Bad) apoptotic members of the 
Bcl-2 family interact with each other to regulate the fine line between the life and death 
of a cell through modulating opening of the MPT pore.  There is considerable evidence 
that the adenosine receptors may be involved in regulation of apoptosis and necrosis 
(Walker et al., 1997; Huang et al., 2001; Liu et al., 2002; Lee et al., 2003).  Control of 
apoptosis potentially is through regulation of Bcl-2 family proteins via reversible 
phosphorylation.  Phosphorylation of Bcl-2 family proteins regulates translocation, 
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degradation and interactions of these proteins with other members of the family 
(Breitschopf et al., 2000).  Bcl-2 family proteins possess protein kinase consensus sites 
specific for ERK 1/2 suggesting that adenosine-mediated regulation of apoptosis could be 
due to activation of ERK 1/2 and subsequent phosphorylation of Bcl-2 family proteins.  
Adenosine has been shown to activate ERK 1/2 in perfused rat heart through activation of 
all 4 adenosine receptors (Germack and Dickenson, 2004).  Similarly A1AR activation by 
the specific agonist R-PIA resulted in the phosphorylation of ERK (1/2) in SH-SY5Y 
cells.  Though a direct link between ERK (1/2) activation and BAD (Bcl-2 associated 
death protein phosphorylation was not made the temporal expression of phospho-BAD 
suggests that ERK(1/2) activation is responsible for phosphorylation of BAD.  This is 
also supported by studies into hypoxia induced phosphorylation of BAD in glioblastoma 
cells where BAD phosphorylation was shown to be mediated by ERK (1/2) activation 
(Merighi et al., 2007).  Phosphorylation of BAD antagonizes its pro-apoptotic function 
resulting in cellular protection against apoptotic stimuli.  Exposure to 1,3-DNB resulted 
in regional specific activation of ERK 1/2 in the brainstem of rats (unpublished data) 
supporting a potential role of adenosine signaling in 1,3-DNB mediated neurotoxicity.   
Additional evidence for adenosine receptor signaling playing a role in 1,3-DNB 
intoxication includes the observed increase in regional blood flow to areas affected by the 
toxin (Mulheran et al., 1999). In addition to neuroprotection, astrocytes also have been 
shown to alter endothelial cell structure and function.  Nitroaromatic-mediated 
neurotoxicity, like the related conditions of acute energy deprivation syndromes, appear 
to involve a strong vascular component, with increases in regional blood flow, reversible 
breakdown of blood brain barrier function and frequent occurrence of petechial 
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hemorrhaging.  Astrocytes form intimate contact with cerebral vasculature through 
projections of cellular processes, terminating in the form of end-feet, which engulf the 
endothelial cells.  Astrocyte–endothelial interactions have profound reciprocal effects on 
each cell type.  Astrocytes show inductive function of many BBB features on endothelial 
cells such as establishment of tight junctions, and expression and polarization of specific 
transporters (i.e. glucose transporter ; GLUT1).   
The vasodilatory effects of adenosine receptor activation are well documented and 
are believed to be mediated through A2 adenosine receptors.  Intrahippocampal injections 
of a nonspecific agonist to adenosine receptors induce a marked, regional, and sustained 
increase in cerebral blood flow (CBF).  Administration of a select A2aAR agonist also 
causes a global increase in CBF (Kochanek et al., 2005).  This increase in CBF in 1,3-
DNB neurotoxicity is most likely a compensatory action in order to increase the delivery 
of metabolic substrates to combat the decline in energy charge.  In 1,3-DNB intoxication, 
one key structural change, which occurs as lesion progresses, is the retraction of 
astrocytic perivascular foot processes.  This interruption of the relationship between 
astrocytes and vascular endothelial cells may be responsible for the BBB breakdown and 
loss of vascular control.  The effects of astrocyte input on vascular endothelial cells were 
previously studied with respect to 1,3-DNB exposure (Romero et al., 1996).  In single 
cultures astrocytes appear to be substantially more sensitive to 1,3-DNB than endothelial 
cells. Endothelial cells showed increased severity in 1,3-DNB damage upon culturing 
with astrocytes.  Alteration in basal metabolic rate of endothelial cells was one proposed 
mechanism.  Additionally, activation of A2aAR has also been shown to mediate astrocyte 
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proliferation (Hindley et al., 1994), which is also seen upon removal of the toxic insult in 
1,3-DNB toxicity. 
  In conclusion, astrocytes play major roles in both neurophysiology and 
neuropathogy.  In the present study the astrocyte cell model DI TNC-1 was able to rescue 
metabolically impaired SH-SY5Y cells from the cytotoxic effects of 1,3-DNB exposure.  
This protection maybe due to the nutritive role astrocytes play, either through the 
maintenance of neuronal ATP pools by shuttling metabolic substrates, or through the 
induction of increase antioxidant capacity of the neurons.  The observation that the 
adenosine receptor antagonist, DPCPX, was able to block the protective effects of co-
culturing suggests that adenosine signaling pathways play a role in the protective 
mechanism.  The diminution of SH-SY5Y excitability, as well as the induction of both 
phospho-ERK (1/2) and phospho-BAD resulting from adenosine receptor activation are 
two potential mechanisms astrocyte derived adenosine may preclude cytotoxicity.  
Further investigation into the complex relationship between astrocytes and neurons in this 
model of AEDS is required and may lend some insight into the regional and cell specific 
selectivity of these conditions.        















































Figure 4-1.  (A) Representative photomicrographs showing differential sensitivity 
between SY5Y neuroblastomas and DI TNC-1 astrocytes.  Both cell types were dosed 
with either, DMSO, 500 µM 1,3-DNB or 1 mM 1,3-DNB for 24 hr.  DI TNC-1 showed 
the classical changes including cellular swelling and extensive vacuolation at 500 µM 
and increased cell loss at 1 mM.  at 500 µM 1,3-DNB, substantial loss of SY5Y cells are 
apparent with almost complete loss at 1 mM 1,3-DNB.  (B)  Representative 
photomicrographs depicting the protective effects of co-culturing SY5Y cells with DI 
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Figure 4-2.  Co-culturing SY5Y neuroblastoma cells with the astrocyte cell line DI TNC-
1results in significant protection against 24 hr exposure to 1,3-DNB (10 µM – 1000 µM) 
Cell viability was assessed by MTT reduction.  Data presented as mean percent MTT 
reduction +/- SE compared to DMSO control.  (*) denotes significant difference from 
DMSO control (P<0.01) (n=6).  (a) denotes significant difference from SY5Y alone 

























































Figure 4-3. Co-culturing SY5Y neuroblastoma cells with the astrocyte cell line DI TNC-
1 results in significant protection against 1,3-DNB (500 µM) induced cell death at 24 hr.  
Cell death was determined by Western blotting for cleaved caspase-3.  Pre-incubation of 
SY5Y with the specific A1 adenosine receptor antagonist 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX) (250 nm) prevented the protection and resulted in an 




















































Figure 4-4.  Activation of A1R in SY5Y neuroblastomas Increases Phospho-ERK and 
Phospho-Bad Protein Expression (A). Graphical representation of mean pixel intensity 
ratios normalized to β-tubulin expression.  Neurons were incubated with either adenosine 
deaminase (ADA) (10 U/mL) for 36h or R-PIA (100 nM) for various time points. Lane 1 
= ADA; Lane 2 0h R-PIA; Lane 3 1h R-PIA; Lane 4 2h R-PIA; Lane 5 4h R-PIA.  ADA 











































Figure 4-5.  Adenosine pre-treatment of SY5Y neuroblastomas silences KCl-induced 
calcium waves.  (A) representative, confocal images of calcium wave propagation 
induced by KCl (25mM).  (B) Adenosine pre-incubation (5 nM , 20 min) resulted in the 
delay of calcium wave induction as well as a reduction in the overall magnitude.  These 
effects were reverse by the adenosine receptor antagonists DPCPX (250 nM) and 






























Figure 4-6.  1,3-DNB (500 µM) treatment of the type 1 astrocyte cell line (DI TNC-1) 
results in increased extracellular concentrations of both AMP and adenosine.  
Representative HPLC chromatograms of acid extracted extracellular adenyl purines from 
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Conclusions, Limitations, and Future Directions 
 
 The research presented in this dissertation provides strong evidence for the 
involvement of α-ketoacid dehydrogenase complexes, specifically the pyruvate 
dehydrogenase complex (PDHc), in the neurotoxic mechanism of the nitroaromatic 
compound, 1,3-dinitrobenzene (1,3-DNB).  Much of the research surrounding the 
neurological deficits produced by this important industrial compound has focused mainly 
on determining the discriminating factors that ultimately are responsible for both the cell-
specific and regional susceptibility differences encountered.  A great deal of evidence has 
pointed to selective metabolic disruption compounded by regional metabolic demand but 
lacking from this body of research are detailed descriptions on the mechanisms by which 
this particular neurotoxicant may elicit metabolic impairment in the sensitive cells.  To 
further expose, as well as understand what characteristics render one particular cell 
population prone to injury over another, it is necessary to identify what specific targets in 
the cell are compromised.  By revealing these targets, therapeutic approaches may be 
devised not only for potential exposure to 1,3-DNB and other nitroaromatic compounds, 
but more importantly for analogous conditions of acute energy deprivation. 
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1,3-Dinitrobenzene selectively inhibited purified pyruvate dehydrogenase complex but 
did not alter α-ketoglutarate complex activity while the reductive metabolite 3-
nitrosonitrobenzene inhibited both complexes.  
 
Mitochondrial dysfunction is a common occurrence in the pathogenesis of many 
diseases that predominantly affect the central nervous system (CNS).  Loss of essential 
metabolic enzymes would greatly hamper the ability of the cell to maintain sufficiently 
high ATP levels to function properly.  Pyruvate dehydrogenase complex (PDHc) is a 
gatekeeper for the TCA cycle, controlling entry of pyruvate into mitochondrial energy 
metabolism (Yeaman, 1989).  Disruption at this site would result in cessation of oxidative 
energy metabolism and ultimately result in neuropathological responses.  Defects in this 
enzyme have been implicated in numerous diseases of the CNS, most notably, cerebral 
ischemia/reperfusion and various neurodegenerative diseases (Mizuno et al., 1994; Kish, 
1997; Martin et al., 2005).    
 1,3-Dinitrobenzene is one of many metabolic disruptors known to induce 
neuropathology reminiscent of acute energy deprivation syndromes.  In purified enzyme 
preparations, this neurotoxic chemical resulted in the rapid and dose-dependent inhibition 
of PDHc (Chapter 2).  Interestingly, 1,3-DNB did not substantially affect α-ketoglutarate 
dehydrogenase complex (KGDHc) suggesting a fundamental difference between the two 
complexes.  In contrast to 1,3-DNB, the reductive metabolite, 3-nitrosonitrobenzene (3-
NNB) showed no discrimination between the two complexes with respect to its ability to 
inhibit them.  3-nitrosonitrobenzene maybe able to directly interact with the complex 
while 1,3-DNB needs to undergo metabolism prior to inhibition.  The observation that 
1,3-DNB did not effectively inhibit KGDHc precluded any non-specific effects of 1,3-
DNB on components of the assay, such as cofactors, since all reaction components but 
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the specific α-ketoacid were exactly the same.  This conclusion points a direct interaction 
of 1,3-DNB with a component of the complex.   
Future studies into the detailed mechanism of inhibition of the α-ketoacid 
dehydrogenase complexes by both 1,3-DNB and 3-NNB are needed.  Utilizing protein 
mass spectrometry, it maybe possible to determine the specific site of interaction between 
the inhibitor and complex.  Additionally, the differential effect of 1,3-DNB on the two 
enzymes raises interesting mechanistic questions and offers a powerful tool to probe 
differences between these two extremely similar enzyme complexes.  One such potential 
difference is the absence of the E3 binding protein (E3BP) component in KGDHc.  The 
lack of this component may render KGDHc insensitive to inhibition by 1,3-DNB.  It 
would be of great interest to determine the effects of 1,3-DNB on the branch chain α-
ketoacid dehydrogenase complex, which, similarly to KGDHc, lacks an E3 binding 
protein (E3BP).  This would allow for the further investigation into the role of the E3BP 
component in the reduction of PDHc activity by 1,3-DNB.  Along the same lines, using 
PDHc from gram-negative bacterium (Bacillus stearotermophilus), which also does not 
possess an E3BP, would also lend insight into the mechanism of inhibition.  The presence 
of the E3BP, in PDHc, may allow for shuttling of reductive metabolites including 3-
NNB, if the E3 component (Lipoamide Dehydrogenase) is the enzyme responsible for 
reductive metabolism of 1,3-DNB.  Lipoamide dehydrogenase has previously been 
shown to possess nitroreductase activity (Tsai, 1987) but whether this enzyme is 
responsible for reductive metabolism of 1,3-DNB or other nitroaromatic compounds 
remains to be shown.  The potential involvement of the E3BP in the inhibitory function 
of 1,3-DNB on PDHc would also provide a means for studying the role of E3BP in PDHc 
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catalysis.  The function of E3BP is believed to be purely structural despite the presence of 
a bound lipoic acid, due to the absence of detectable transacetylase activity (Harris et al., 
1997).  The toxicant 1,3-DNB may potentially be used as a tool to probe the E3BP’s role 
in catalytic function of the pyruvate dehydrogenase complex. 
 
Pyruvate dehydrogenase complex is inhibited in an isomer-specific manner by 
dinitrobenzene.       
 
A curious feature of 1,3-DNB is that it is the only isomer of dinitrobenzene that 
confers neurotoxicity.  It has been proposed that the isomer specificity with respect to 
induction of neuropathology is mainly due to the preferred routes of metabolism each 
isomer undergoes (Nystrom and Rickert, 1987). The 1,2- isomer predominantly 
undergoes conjugation with GSH while 1,4-Dinitrobenzene undergoes rapid reduction 
followed by conjugation.  In contrast to these two isomers, 1,3-DNB exclusively 
undergoes nitroreduction.  Interestingly, both the 1,4- and 1,3- isomers induce 
methemoglobinemia with the 1,4- being more potent (Cossum and Rickert, 1985).  This 
precludes the hypothesis that methemoglobinemia plays a role in 1,3-DNB induced 
neurotoxicity.  Examination of the effects of the three different isomers on PDHc activity 
showed that both the 1,2- and 1,3- isomers inhibit the complex equally but that the 1,4-
isomer showed greatly diminished inhibitory action towards this enzyme complex.  
Isomer specificity was also shown to play a role in PDHc meditated production of N-
hydroxy-N-arylacetamides, in the presence of various nitroso-aromatics (Yoshioka and 
Uematsu, 1993; Yoshioka et al., 1996).  In these studies it was established that bulky 
para-substituents on the aromatic ring of nitrosoaromatics reduced the efficiency by 
which these compounds could be metabolized to their respective N-hydroxy-N-
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arylacetamide products.  This selectivity was attributed to the steric hindrance in the E1 
active site of PDHc.  This similarity between the metabolism of nitrosoaromatics and the 
inhibition by 1,3-DNB suggests a common mechanism of action and points to the E1 
active site as the point of inhibition.  This hypothesis is further supported by the ability of 
3-NNB to potently inhibit the function of the E1 component when separated from the 
complex.   
Future studies examining the ability of 1,3-DNB and other nitroaromatics to act as 
substrates in the production of N-hydroxy-N-arylacetamides are needed.  This could be 
accomplished through quantification of the arylacetamide product by HPLC (Yoshioka 
and Uematsu, 1993; Yoshioka et al., 1996).  Additionally, it would be of interest to 
quantify their production in both cell culture and in whole animal as a potential marker to 
probe if regional metabolism of these nitroaromatic compounds occurs.  There may also 
exist differential cellular capability to metabolize these compounds that could confer the 
cell specific sensitivity observed in 1,3-DNB neurotoxicity. 
 
Irreversible inhibition of PDHc by 1,3-dinitrobenzene required both the presence of 
thiamine pyrophosphate and pre-activation by the substrate pyruvate.  
 
Incubation of PDHc with high concentrations of 1,3-DNB followed by the 
effective dilution of the inhibitor resulted in the degree inhibition corresponding to the 
diluted concentration.  This finding was initially assumed to mean that 1,3-DNB did not 
irreversibly inhibit the complex through covalent binding.  Subsequent experiments, 
investigating the requirement of substrates for inhibition, confirmed that the initial 
assumption was wrong.  In the presence of both thiamine pyrophosphate and pyruvate, 
the level of inhibition achieved corresponded to the initial concentration of inhibitor.  
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This supports the notion that 1,3-DNB effectively inhibits the complex through 
irreversible binding.  It also suggests that the 2-hydroxyethylidene-TPP carbanion formed 
after decarboxylation of pyruvate maybe the predominant site affected by nitroaromatic 
compounds.  The mechanism of how this may occur is not entirely clear.  The carbanion 
is a potent nucleophile that can react strongly with an electrophile.  This carbanion 
normally undergoes nucleophilic attack of the oxidized lipoic acid on the E2 component 
of the enzyme.  The strong electophilic nature of 3-NNB predisposes this compound to 
attack by the bound carbanion.  This explains the ability of 3-NNB to potently inhibit the 
separated E1 component enzyme.  Additionally it also explains why 1,3-DNB was less 
effective in inhibiting this reaction.  The observation that the overall reactivity of the 
complex was inhibited to a greater extent by 1,3-DNB compared to the E1 component 
suggests a requirement of the other components, potentially metabolizing 1,3-DNB to a 
species capable of undergoing nucleophilic attack by the E1 bound carbanion.  
Future studies into the involvement of the 2-hydroxyethylidene-TPP in inhibition 
of PDHc by 1,3-DNB maybe conducted using proton NMR (H1 NMR).  Previous studies 
investigating the catalytic cycle of thiamine dependent enzymes showed that H1 NMR 
could be use to detect reaction intermediates during catalytic function of pyruvate oxidase 
(Wille et al., 2006).  Pyruvate oxidase catalyzes the same initial reaction that PDHc-E1 
catalyzes, namely, decarboxylation of pyruvate to form a 2-hydroxyethylidene-TPP 
carbanion.  The ability of 1,3-DNB or 3-NNB to interact with the carbanion should be 
able to be determined using H1 NMR with a change in chemical shift corresponding to the 
adduct.    
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1,3-Dinitrobenzene induced metabolic impairment in the astrocyte-derived cell line C6 
glioma. 
  
Lactic acidosis is a presenting feature in many metabolic disorders affecting 
mitochondrial aerobic energy metabolism.  Increased concentrations of extracellular 
lactate in susceptible regions of CNS during 1,3-DNB induced encephalopathy have been 
previously observed (Phelka et al., 2003), suggesting that disruption of mitochondrial 
metabolic enzymes underlie the resultant neuropathology.  Similarly, using the astrocyte-
derived cell model, C6 gliomas, 1,3-DNB exposure produced dose-dependent increases 
in lactate production and release (Chapter 3). Though in vitro models do not always 
mimic the responses seen in the whole animal, the ability of 1,3-DNB to elicit similar 
biochemical responses, in culture, support the notion that the initial biochemical defect 
responsible for cytotoxicity of astrocytes is most likely the same in both in vivo and in 
vitro situations.  This conclusion allows for the use of this particular model to examine 
metabolic targets affected by 1,3-DNB.  Though the initial target maybe the same, due to 
the intimate relationship of cell types within the CNS, and the ability of intercellular 
signaling to modulate cellular responses, especially with respect to energy metabolism, 
the progression of cytotoxicity potentially cannot be studied without proper inputs of 
neighboring cell types.  An additional limitation is the use of a cancer cell line as a model 
for astrocytes.  Though cancer cell lines offer many advantages over both primary cells 
and in vivo models, namely time and expense, there are some disadvantages that must 
also be considered.  The most important concern when using cancer cell lines is loss of 
cellular characteristics that define the cell from which they were derived.  One example 
of a characteristic change between cancer cell lines and primary cells is energy 
metabolism.  Altered glycolytic rates and changes in glycogen utilization have both been 
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described in glioma cell lines (Galarraga et al., 1986).  The differences between cancer 
cell lines and primary cells must be carefully considered when interpreting data. 
To further establish C6 gliomas as a representative model for astrocytes in 1,3-
DNB neurotoxicity.  Morphological changes were examined upon exposure to 1,3-DNB.  
Astrocytes in sensitive regions in the CNS undergo distinctive morphological changes 
that include edematous swellings, extensive vacuolation, and retraction of peri-vascular 
and peri-neuronal end foot processes (Philbert et al., 1987).  Similar morphological 
changes were observed in culture using C6 gliomas with extensive and progressive 
vacuolation being the most pronounced alteration.  Cellular swelling occurred to some 
degree as cytotoxicity progressed, potentially due to the accumulation of lactic acid in the 
extracellular environment with subsequent acidification.  Astrocytes are exquisitely 
sensitive to acidosis induced cellular swelling, specifically when mediated by lactic acid 
(Staub et al., 1990).  With similar changes in both morphology and biochemical 
parameters, C6 gliomas appeared to be a sufficient model to examine biochemical targets 
of 1,3-DNB. In addition to early biochemical changes, significant changes in the 
morphology of astrocytes occur in the CNS of 1,3-DNB and other AEDS. 
 
The alternative energy substrates acetoacetate and acetyl-carnitine protected C6 glioma 
from the cytotoxic effects of 1,3-DNB supporting PDHc as the site of interference.   
 
The ability of the alternative fuel sources, acetoacetate and aceytl-carnitine, to 
reverse many of the morphological and biochemical changes induced by 1,3-DNB points 
to the primary defect being prior to TCA cycle metabolism, due to the fact that both of 
these substrates can be converted to acetyl-CoA and subsequently enter metabolism at the 
point of citrate synthase (Edmond, 1992; Zanelli et al., 2005).  Under normal 
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physiological conditions, the human adult brain, exclusively, or at least preferentially 
oxidizes glucose to meet its energetic needs.  During postnatal development or periods of 
starvation the brain can adapt to the utilization of ketone bodies to maintain energy 
charge.  The ketone body acetoacetate is converted to two molecules of acetyl-CoA.  
Similarly, Acetyl-carnitine has also been shown to serve as an exogenous source of 
acetyl-CoA.  This process has been exploited in order to deliver energy substrates during 
times of energy deprivation, including ischemia/reperfusion injury as well as pyruvate 
dehydrogenase deficiency (Weber et al., 2001; Zanelli et al., 2005).  The inability of free 
acetate and L-carnitine to confer protection, points to the availability of the acetyl moiety 
for usage in energy metabolism as the neuroprotective mechanisms of these substrates.  
Though it is most likely the conversion of acetyl-carnitine to acetyl-CoA and further 
oxidation through the TCA cycle that cause the reduction in lactate concentrations and 
maintenance of ATP levels, other potential mechanism maybe in involved.  Acetyl-
carnitine has been shown to reduce oxidative stress in cerebral ischemia/reperfusion, as 
well as with treatment of A-beta amyloid through either direct reduction of mitochondrial 
redox state or indirectly through induction of antioxidant genes (Liu et al., 1993; 
Calabrese et al., 2005).  There is the potential that acetyl-carnitine may protect against 
the effects of 1,3-DNB induced oxidative stress instead of through direct action as a 
metabolic substrate. 
  
Exposure of C6 glioma cells to 1,3-DNB resulted in loss of PDHc and KGDHc activity 
potentially through modification of protein bound lipoic acid. 
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Cytochemical quantification of residual PDHc and KGDHc activity in the C6 
glioma cell line showed dose dependent reductions in both PDHc and KGDHc activity. 
The differential sensitivity between the two complexes observed with purified enzymes 
mimics the results obtained from intact cells with PDHc again being more sensitive to 
inhibition.  At high concentrations of 1,3-DNB, KGDHc in cells was inhibited to a 
greater extent than observed with the purified complex.  Potentially, cell-mediated 
bioactivation of 1,3-DNB to its reductive metabolite, 3-nitrosonitrobenzene (3-NNB), 
resulted in the increased inhibition seen in culture, compared to the purified enzyme.  
This is supported by the significantly increased inhibitory effects of 3-NNB on purified 
enzyme preparations of KGDHc.  Alternatively, oxidative stress due to redox cycling of 
1,3-DNB, in intact cells, may underlie the increased inhibition of KGDHc. 
Though 3-NNB showed strong inhibitory action toward the separated E1 
component, the observation that 3-NNB was able to interfere with 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB) metabolism by PDHc also supports the interaction of 3-NNB 
with the reduced thiols of protein bound lipoic acid.  Numerous nitrosoaromatics have 
been shown to react strongly with reduced thiols, such as those present in reduced 
glutathione (Eyer, 1979; Eyer and Schneller, 1983; Umemoto et al., 1988; Cribb et al., 
1991).  Adduction of reduced lipoic acid is a common mechanism of inhibition.  This site 
is believed to be the point of impairment by many arsenical compounds, which are classic 
inhibitors of PDHc.  The ability of 1,3-DNB exposure to result in changes in the lipoic 
acid site of PDHc was demonstrated through using an antibody that specifically 
recognizes native lipoic acid.  This antibody has previously been used to explore the 
effects of 4-hydroxy-2-nonenal (4-HNE) in which modification of lipoic acid by 4-HNE 
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resulted in loss of immunoreactivity (Humphries and Szweda, 1998).  Likewise, exposure 
of C6 glioma cells to 1,3-DNB resulted in loss of immunoreactivity in both a time and 
dose dependent manner indicating that modification of lipoic acid occurs during exposure 
to 1,3-DNB.  Interestingly, the treatment of C6 gliomas with two classic arsenic 
containing compounds, phenyl arsine oxide, and arsenic trioxide, at concentrations that 
have previously been shown to completely inhibit the complex (Samikkannu et al., 
2003), showed no significant loss of lipoic acid immunoreactivity, even though 
significant loss of cell viability was apparent.  The reason for this observation is unclear, 
but it does suggest that 1,3-DNB potently affects lipoic acid and further supports the 
hypothesis that 1,3-DNB renders it inhibitory action through modification of protein 
bound lipoic acid.                         
In Chapter 2, it was established that 1,3-DNB and its metabolite, 3-NNB, 
effectively inhibit the PDHc complex in purified enzyme preparations.  The inhibitory 
actions of 1,3-DNB on PDHc were confirmed in intact cells. This inhibition appears to be 
a result of protein modification of E2 bound lipoic acid.  Exposure of C6 gliomas to 1,3-
dinitrobenzene resulted in a dose- and time-dependent reduction in lipoic acid 
immunoreactivity.  This loss in immunoreactivity correlated with the increase in protein 
carbonylation of mitochondrial proteins that correspond to the molecular weights of the 
E2 components of both PDHc and KGDHc.  Protein oxidation and subsequent protein 
dysfunction is a common occurrence during oxidative stress.  Numerous proteins are 
predisposed to oxidation including those that possess critical cysteines due to the 
susceptible sulfur atom (Shacter, 2000).  Protein oxidation can introduce carbonyl groups 
into the protein, which can be detected through derivatization by 2,4-
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dinitrophenylhydrazine to the corresponding hydrazone.  The proteins that are 
carbonylated are then probed using a specific antibody that recognizes the 2,4-
dinitrophenyl (anti-2,3-DNP) group attached to the protein (Keller et al., 1993).   The 
increased carbonylation of proteins corresponding to the molecular weight of the E2 
components suggests that loss of lipoic acid is potentially due to increased protein 
oxidation after induction of oxidative stress by 1,3-DNB.  The inability of both 
antioxidants and thiol containing compounds to attenuate the loss of LA 
immunoreactivity contradicts this conclusion.  Though protein not derivatized by 2,4-
dinitrophenylhydrazine shows no reactivity with the anti-2,4-DNP antibody there maybe 
the potential for 2,4-dinitrophenylhydrazine to react with the 1,3-DNB adduct resulting in 
detection by the antibody.  In order to confirm that the loss of LA was not due to 
oxidation by lipid peroxidation products, total cellular protein was probed with an anti-4-
hydroxy-2-nonenal antibody.  No significant dose-dependent bands were detected.  This 
does not rule out other lipid peroxidation products from being responsible for the LA loss 
or for direct oxidation by reactive oxygen species but it would be expected that if lipid 
peroxidation did occur, 4-hydroxy-2-nonenal adducts would be apparent.   
Future studies are required in order to describe the exact mechanism of inhibition 
of PDHc by 1,3-DNB.  Though the bands that possess carbonylated proteins correspond 
to the molecular weights of the E2 components of PDHc and KGDHc, 2D gel 
electrophoresis followed by protein mass spectrometry is needed to definitively identify 
these proteins.  Additionally, mass spectral analysis may allow for the identification of 
the exact adduct responsible for loss of lipoic acid immunoreactivity.  It would also be of 
interest to look for loss of lipoic acid immunoreactivity and carbonylated proteins using 
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Western blot analysis in brain tissue samples from rats exposed to 1,3-DNB.  This could 
also be done using immunohistochemistry in order to correlate regional distribution of 
lipoic acid loss and carbonylation with lesion presentation.                              
 
Co-culturing with DI TNC-1 cells protected against the cytotoxic effects of 1,3-DNB on 
SH-SY5Y. 
  
In addition to uncovering metabolic targets of 1,3-DNB, responsible for induction 
of acute energy deprivation, this thesis also examines the role astrocytes play in shielding 
neurons from the cytotoxic effects of metabolic disruption.  A hallmark of acute energy 
deprivation syndromes is the relative sparing of neurons prior to substantial loss of the 
supportive astrocyte cells (Philbert et al., 1987; Cavanagh, 1988; Cavanagh, 1993).  
Though astrocytes have traditionally been thought of as being less susceptible to cellular 
stresses then their neuronal counterparts there is growing evidence that astrocyte 
dysfunction may precede neuronal loss in numerous neurological disorders including 
focal ischemia and neurodegenerative diseases (Liu et al., 1999; Maragakis and 
Rothstein, 2006).  Several studies have shown the ability of astrocytes to modulate the 
toxic responses of both neuronal and endothelial cells (Chen et al., 2001; Swanson et al., 
2004; Rao et al., 2005; Cao et al., 2007).  Utilizing the type 1 astrocyte-derived model, 
DI TNC-1, and the neuronal SH-SY5Y neuroblastoma, the interactions of astrocytes and 
neurons during conditions of metabolic impairment were studied.  In single culture, SH-
SY5Y cells were highly sensitive to the cytotoxic effects of 1,3-DNB including loss of 
mitochondrial reducing potential, substantial morphological changes as well as the 
induction of cell death as determined by caspase-3 activation.  Contrary to observations 
in vivo, the astrocyte-derived DI TNC-1 cells, in single culture, are relatively insensitive 
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compared to SH-SY5Y.  Co-culturing SH-SY5Y cells with DI TNC-1 cells, protected 
SH-SY5Y cells from the deleterious effects of 1,3-DNB.   
 In the co-culture studies conducted, transwell inserts were used, which allowed 
for soluble factors to reach both cell type, but prevented direct contact between the cells.  
In vivo, astrocytes and neurons form intimate contacts and it would be interesting to 
determine if direct contact between the cell types altered the responses of each cell type 
to 1,3-DNB.  In culture this would be somewhat difficult due to the inability to 
differentiate individual cell type responses but the use of acute brain slices may offer a 
better model to investigate intercellular communication in pathology progression during 
1,3-DNB intoxication.  In addition to using brain slices, primary cells may also offer a 
better understanding of the complex relationships between astrocytes and neurons.  Cell 
lines offer many advantages over both primary cell culture and in vivo studies but a major 
concern when using cell lines is the loss of characteristics that define the cell they are 
supposed to model.  An example of this that is relevant to studies conducted in this thesis 
is the observation that C6 glioma cells unlike primary astrocytes, do not release 
adenosine due to the absence of an AMP-preferring 5’nucleotidase expression (Parkinson 
et al., 2006).  Use of C6 gliomas to study intercellular adenosine signaling may have 
resulted in completely different results and altered conclusions.  Future studies will 
employ either primary cells or brain slices to better mimic the response in the whole 








Blockage of the A1 adenosine receptor negated the protective effects of co-culturing 
SH-SY5Y cells with DI TNC-1 
 
The use of the A1 adenosine receptor antagonist (DPCPX) reversed the protective 
mechanism of co-culturing SH-SY5Y cells with DI TNC-1 cells, suggesting that this 
potent intercellular signaling molecule plays a key role in the neuroprotection afforded by 
astrocytes.  The retaliatory function of adenosine is well established (Kochanek et al., 
2005; Stone, 2005).  During times of metabolic imbalance, such as seen in ischemia, 
extracellular adenosine concentrations dramatically increase resulting in the activation of 
corresponding adenosine receptors.  Treatment with the metabolic disruptor, 1,3-DNB 
increased extracellular adenosine, as well as AMP concentrations.  Though the increase 
in adenosine concentrations were only in the nanomolar range, this increase is significant 
enough to result in the activation of the A1 receptor.  Increases in extracellular adenosine 
levels are achieved either through release of intercellular adenosine or release of adenine 
nucleotides with subsequent metabolism by ectonucleotidases present on the plasma 
membrane.  The substantial accumulation of AMP maybe a result of low expression of 
ecto-nucleotidases in DI TNC-1 cells that would normally metabolize AMP to adenosine.  
Alternatively the slight increase in adenosine maybe the result of rapid metabolism of 
adenosine by adenosine deaminase.   
Further studies into the expression profile for enzymes and transporters involved 
in regulating adenosine levels are needed.  It would also be of interest to see if activation 
of A1 adenosine receptor in single cultures of SH-SY5Y cells is sufficient to protect these 
cells from 1,3-DNB toxicity.   
   
 139 
Activation of A1 adenosine receptors in SH-SY5Y cells resulted in the induction of pro-
survival mechanisms.  
 
Activation of the A1 adenosine receptor acts to silence neuronal activity in the 
effort to reduce metabolic demand.  This neuroprotection is mediated by many 
intracellular signaling pathways that result in hyperpolarization of neurons, decreased 
neurotransmitter release, as well as induction in the expression of pro-survival proteins 
(Drury and Szent-Gyorgyi, 1929; Dunwiddie and Masino, 2001; Kochanek et al., 2005).  
All three pathways were shown to occur in SH-SY5Y neuroblastoma cells upon 
activation with either adenosine or the A1 specific agonist R-PIA.  Treatment of SH-
SY5Y cells with R-PIA resulted in the phosphorylation of the extracellular signal-
regulated protein kinase (ERK), a member of the mitogen activated protein kinase 
(MAPK) family.  MAPK are involved in a wide array of cellular processes including cell 
cycle progression, proliferation, differentiation and apoptosis (Grewal et al., 1999).  
Activation of MAPK results in the phosphorylation of numerous transcriptional factors as 
well as various other proteins most notably those involved in regulating cell death (i.e. 
Bcl-2 family proteins) (Breitschopf et al., 2000).  Interestingly, addition of adenosine 
deaminase resulted in loss of phospho-ERK suggesting a basal activation by adenosine of 
the ERK pathway.  Subsequent to ERK activation, phosphorylation of the pro-apoptotic 
Bcl-2 family protein Bad (Bcl-2 associated death protein) occurs.  The balance between 
anti-apoptotic (Bcl-2, Bcl-xl) and pro-apoptotic (Bax) members of the Bcl-2 family 
proteins is believed to regulate apoptosis.  Active Bad binds to Bcl-xl, antagonizes the 
anti-apoptotic action of this protein.  Upon induction of cell survival pathways Bad can 
be phosphorylated resulting in its sequestration by 14-3-3 in the cytosol (Zha et al., 
1996).  Two known pathways for Bad phosphorylation are through the PI3K/AKT 
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pathway and ERK.  Though a direct link between ERK activation and Bad 
phosphorylation was not made in the current study, the ability of ERK to phosphorylate 
Bad has been well established (Jin et al., 2002).  The temporal expression profile also 
supports the involvement of ERK in Bad phosphorylation. 
Future studies are needed to uncover the detailed intracellular signaling pathways 
responsible for the neuroprotection observed with co-culturing astrocytes with neurons.  
Use of a MEK inhibitor, which is the upstream kinase responsible for activation of ERK, 
will determine if ERK activation is necessary for Bad phosphorylation.  Modulating 
expression levels of Bad through knockdown as well as over-expression of the protein 
will also help determine Bad’s role in controlling induction of cell death in 1,3-DNB 
exposure.    
    In addition to induction of anti-apoptotic signaling pathways, adenosine 
receptor activation results in cessation of neural transmission.  In the present study, 
adenosine silenced KCl- induced calcium waves in SH-SY5Y cells.  The action of 
adenosine was determined to be solely mediated through activation of the A1 adenosine 
receptor due the restoration of neuronal excitability with treatment of the A1 specific 
antagonist, DPCPX.  Depression of neuronal activity mediates neuroprotection through 
counteracting release of potentially excito-toxic neurotransmitters as well as preventing 
persistent membrane depolarization through activation of ionotropic glutamate receptors.  
Though these studies show the potential involvement of purinergic signaling in the 
neuroprotection during 1,3-DNB exposure, further investigation into the role adenosine 
signaling may play in the cell and regional sensitivity of AEDS is required.   
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The use of brain slices maybe useful in determining if neuronal silencing 
mediated the observed neuroprotection in the co-culture studies.  Measuring neuronal 
depolarization after 1,3-DNB treatment would show if neuronal activity was depressed 
and use of adenosine receptor antagonists would determine if the depression was 
mediated through adenosine.  
  
Overall Significance 
Most of the studies on 1,3-DNB have concentrated on determining the underlying factors 
of  the regional and cell specific sensitivity observed with this neurotoxicant.  This thesis 
is the first attempt at identifying direct targets of 1,3-DNB that are responsible for the 
metabolic disruption encountered in 1,3-DNB induced encephalopathy.  The α-ketoacid 
dehydrogenase complexes were demonstrated to be specific metabolic targets affected in 
1,3-dinitrobezene exposure.  Through enzymatic analysis of purified protein, 1,3-DNB 
was shown to directly inhibit the pyruvate dehydrogenase complex, which was further 
confirmed in an astrocyte cell model, C6 glioma.  In this cell type, both PDHc and 
KGDHc were significantly affected during acute exposure to 1,3-DNB. The inhibition of 
these complexes explains the biochemical changes that occur upon exposure to 1,3-DNB.  
The loss of lipoic acid immunoreactivity points to chemical modification of this essential 
cofactor.  The inability of antioxidants and thiol containing compounds to attenuate this 
loss of LA suggests direct modification rather than resulting from induction of oxidative 
stress.  Further investigations into the mechanism of inhibition within intact cells, as well 
as examination of these enzyme complexes in vivo during 1,3-DNB exposure are 
required.   
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Additionally, this thesis presents the first data investigating the role of 
astrocyte/neuronal relationships in the cell specific sensitivity to 1,3-DNB.  The relative 
sparing of neurons in acute energy deprivation syndromes maybe due to the shielding of 
neurons from metabolic impairment rather then an innate insensitivity of neurons to the 
effects of energy deprivation.  This hypothesis is supported by the exquisite sensitivity of 
the neuronal cell model, SH-SY5Y neuroblastomas, to the cytotoxic effects of 1,3-DNB 
when cultured alone and the extensive neuroprotection afforded through culturing with 
the astrocyte model, DI TNC-1.  This protection was shown to be mediated, at least in 
part, through the activation of adenosine receptors.  Indeed, further study on the 
intercellular relationship between neurons and astrocytes during acute energy deprivation 
is required, though the possibility for exploitation of purinergic signaling as a potential 
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